1
|
Matsushita K, Yokoyama S, Hashimoto K, Uchiyama Y, Mizuno T, Kawai K, Kobayashi T, Saso K, Komori T, Kishi K, Fukunaga M. [A Case of Adenocarcinoma of Pancreatic Head of Liver Disfunction after Pancreaticoduodenectomy with Celiac Artery Stenosis Treated by Urgent Median Arcuate Ligament Release]. Gan To Kagaku Ryoho 2024; 51:448-450. [PMID: 38644318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/23/2024]
Abstract
This patient visited our hospital for the purpose of detailed examination of prostate cancer in his seventies. Abdominal contrast-enhanced computed tomography(CT)revealed a low-density mass of 2 cm in the pancreatic head. He was diagnosed with pancreatic cancer. Pancreaticoduodenectomy was performed after 2 courses of gemcitabine and S-1 therapy were performed as neoadjuvant chemotherapy. An intraoperative clamp test of the gastroduodenal artery showed that the pulsation of the common hepatic artery and the proper hepatic artery was weak but sufficient, so the gastroduodenal artery was cut and the operation was completed as planned. A blood test on the 1st day after the operation showed elevated levels of AST 537 U/L, ALT 616 U/L, and 7 hours later blood sampling showed further increases in AST 1,455 U/L, ALT 1,314 U/L. After a detailed review of the preoperative CT, celiac artery stenosis due to compression of the arcuate ligament was suspected, and urgent median arcuate ligament release was performed on the same day. Dissection of the arcuate ligament significantly improved the pulsation of the common hepatic artery and proper hepatic artery. Postoperatively, hepatic enzymes improved and ISGPS showed Grade B pancreatic juice leakage, but the patient was discharged from the hospital on the 49th postoperative day without any other complications. He took S-1 as adjuvant chemotherapy, and no signs of recurrence have been observed 9 months after the operation.
Collapse
|
2
|
Kawai K, Komori T, Saso K, Mizuno T, Uchiyama Y, Kobayashi T, Matsushita K, Kishi K, Yokoyama S, Fukunaga M. [A Case of Strangulated Bowel Obstruction after a Laparoscopic Hartmann's Operation for Rectal Cancer]. Gan To Kagaku Ryoho 2023; 50:384-386. [PMID: 36927917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023]
Abstract
A 98-year-old woman presented with hematochezia and a circumferential type 2 tumor in the rectum Rb identified on fiberoscopy. We a performed laparoscopic Hartmann's operation and D2 lymphadenectomy for advanced rectal cancer. A sigmoid colostomy was created via the intraperitoneal route. On the postoperative day 12, the patient experienced abdominal pain. Computed tomography showed that the small intestine formed a closed loop in the pelvic space. The patient was diagnosed with a strangulated bowel obstruction of the small intestine for which an emergency exploratory laparotomy was performed. The small intestine, which had passed through a defect between the lifted sigmoid colon and the left abdominal wall, was strangulated by the lifted sigmoid colon. We performed partial resection of the small intestine. The patient died on postoperative day 32 of acute deterioration of aortic valve stenosis. There have been few reports of strangulated bowel obstruction resulting from internal hernia associated with colostomy. These findings demonstrate that it is important to select the appropriate route for colostomy creation in each case.
Collapse
Affiliation(s)
- Kunihiko Kawai
- Dept. of Surgery, Hyogo Prefectural Nishinomiya Hospital
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Matsushita K, Yokoyama S, Uchiyama Y, Mizuno T, Kawai K, Kobayashi T, Saso K, Komori T, Kishi K, Oka K, Fukunaga M. [A Case of Retroperitoneal Leiomyosarcoma Resected Radically by Pancreaticoduodenectomy with Vascular Resection]. Gan To Kagaku Ryoho 2022; 49:1953-1955. [PMID: 36733055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
A 54-year-old woman visited to a doctor nearby medical clinic complaining of loss of appetite. She was diagnosed with right hydronephrosis on abdominal ultrasonography, and referred to our hospital for further examination. Contrast abdominal computed tomography(CT)revealed that a 6.2 cm tumor with a contrast-enhancing effect inside in the retroperitoneum near the lower pole of the right kidney. She was diagnosed with hydronephrosis due to infiltration of the right kidney of a retroperitoneal tumor. The tumor was suspected of invading the duodenum and inferior vena cava, but no obvious lymph node or distant metastasis was observed. Abdominal MRI revealed a tumor showed hyperintensity on T2-weighted and diffusion-weighted images. We performed pancreaticoduodenectomy with inferior vena cava resection and right nephrectomy. The pathological diagnosis was leiomyosarcoma originating from retroperitoneum and pT2, pN0, pM0, pStage ⅢA. The postoperative course was good, and she was discharged 10 days after the operation. Thoracoabdominal CT showed a tumor 4 cm at the hepatic hilum three months after surgery, and EOB-MRI showed many tumors other than the same site, so multiple liver metastases were diagnosed as recurrence. Doxorubicin has been started and is still being treated.
Collapse
|
4
|
Mizuno T, Matsushita K, Komori T, Uchiyama Y, Kawai K, Kobayashi T, Saso K, Kishi K, Yokoyama S, Fukunaga M. [A Case of Liver Metastasis Complete Resection for Concurrent Overlapping Cancer of the Transverse Colon and Renal Cell Carcinomas that were Difficult to Differentiate from Hepatocellular Carcinoma]. Gan To Kagaku Ryoho 2022; 49:1811-1813. [PMID: 36733007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
A 79-year-old man visited the hospital because of constipation. Colonoscopy showed a transverse colon carcinoma. Dynamic CT showed a renal neoplastic lesion and 2 lesions in the liver with early staining and late wash out, and the liver lesions showed ring enhancement on EOB-MRI. The preoperative diagnosis was either transverse colon cancer, renal cell carcinoma, hepatocellular carcinoma, or metastatic liver cancer. The patient underwent partial transverse colon resection, partial right nephrectomy, and partial hepatic resection. Additional to the 2 liver lesions in S6, an intraoperative ultrasound showed 1 tumor in S5; therefore, 3 partial hepatectomies were performed. Histopathological findings revealed that the tumors in S5 and S6 were liver metastases of transverse colon cancer and renal cell carcinoma, respectively. The final diagnosis was transverse colon cancer, pT4a, pN0, pM1, pStage Ⅳa and papillary renal cell carcinoma, pT1a, pN0, pM1, pStage Ⅳ. For 9 months postoperatively, there was no apparent recurrence.
Collapse
Affiliation(s)
- Tsuyoshi Mizuno
- Dept. of Gastroenterological Surgery, Hyogo Prefectural Nishinomiya Hospital
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Ejiri K, Ding N, Kim E, Honda Y, Cainzos-Achirica M, Tanaka H, Howard-Claudio C, Butler K, Hughes T, Coresh J, Van't Hof J, Meyer M, Blaha M, Matsushita K. Associations of segment-specific pulse wave velocity with vascular calcification: the Atherosclerosis Risk in Communities (ARIC) Study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Pulse wave velocity (PWV) is a non-invasive measure of arterial stiffness and a predictor of cardiovascular disease (CVD). Vascular calcification, especially coronary artery calcium (CAC) measured by computed tomography (CT), is one of the strongest predictors of CVD but requires radiation for measurement. PWV may be helpful to identify persons with vascular calcification who may benefit from formal assessment of vascular calcification with CT. However, the associations between PWV and vascular calcification across different vascular beds have not been fully investigated.
Purpose
The aims of this study were to quantify the association between PWV and calcification at different segments and to explore whether PWV can identify individuals with vascular calcification beyond traditional risk factors.
Methods
Among 1486 ARIC Study participants (mean age 79.3 [SD 4.2] years), we measured PWV by OMRON VP1000plus at the following segments: heart-carotid (hcPWV), heart-femoral (hfPWV), carotid-femoral (cfPWV), heart-ankle (haPWV), brachial-ankle (baPWV) and femoral-ankle (faPWV). Participants were stratified into four groups based on quartiles of each PWV measure. Dependent (i.e., outcome) variables were high calcium score (≥75th percentile of Agatston score by CT) of the following vascular beds (including valves): coronary arteries, aortic valve ring, aortic valve, mitral valve, ascending aorta, and descending aorta. We ran multivariable logistic regression models and assessed c-statistics as a measure of prediction discrimination.
Results
Only cfPWV was significantly positively associated with high CAC (adjusted odds ratio [OR] for the highest vs. lowest quartile: 1.73 [95% CI: 1.17–2.55]) (green dot in figure). The associations were overall most evident for descending aorta calcification, with significantly positive results for hfPWV (gold dot in figure), cfPWV (green dot), haPWV (emerald dot), and baPWV (blue dot). For example, adjusted OR for the highest vs. lowest quartile of cfPWV was 4.08 (2.70–6.24). hfPWV and cfPWV were significantly associated with mitral valve calcification as well. In contrast, faPWV (purple dots) was inversely associated with calcification of aortic valve ring, ascending aorta, and descending aorta. For descending aorta calcification, even the second highest quartile of the following measures demonstrated significant adjusted OR: hfPWV (3.21 [2.11–4.95]), cfPWV (2.11 [1.40–3.20]), and baPWV (1.75 [1.14–2.69]). Simultaneously adding cfPWV and hfPWV improved c-statistic for CAC (Δc-statistic 0.011 [0.0007–0.022]) and descending aorta calcification (0.035 [0.017–0.053]).
Conclusions
The associations of PWV with vascular calcification varied substantially across segments, with descending aorta calcification most closely linked to PWV measures and cfPWV most robustly associated with calcification of multiple vascular beds. cfPWV and hfPWV, together, improved discrimination of high CAC beyond traditional risk factors.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): The National Heart, Lung, and Blood Institute, National Institutes of Health
Collapse
Affiliation(s)
- K Ejiri
- Johns Hopkins Bloomberg School of Public Health, Epidemiology , Baltimore , United States of America
| | - N Ding
- Johns Hopkins Bloomberg School of Public Health, Epidemiology , Baltimore , United States of America
| | - E Kim
- Johns Hopkins Bloomberg School of Public Health, Epidemiology , Baltimore , United States of America
| | - Y Honda
- Johns Hopkins Bloomberg School of Public Health, Epidemiology , Baltimore , United States of America
| | - M Cainzos-Achirica
- The Methodist Hospital, Preventive Cardiology , Houston , United States of America
| | - H Tanaka
- University of Texas at Austin, Kinesiology and Health Education , Austin , United States of America
| | - C Howard-Claudio
- The University of Mississippi Medical Center, Radiology, Cardiac and Body Imaging , Jackson , United States of America
| | - K Butler
- The University of Mississippi Medical Center, Medicine , Jackson , United States of America
| | - T Hughes
- Wake Forest School of Medicine, Gerontology and Geriatric Medicine , Winston-Salem , United States of America
| | - J Coresh
- Johns Hopkins Bloomberg School of Public Health, Epidemiology , Baltimore , United States of America
| | - J Van't Hof
- University of Minnesota, Cardiovascular Medicine , Minneapolis , United States of America
| | - M Meyer
- University of North Carolina, Emergency Medicine , Chapel Hill , United States of America
| | - M Blaha
- Johns Hopkins University School of Medicine, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease , Baltimore , United States of America
| | - K Matsushita
- Johns Hopkins Bloomberg School of Public Health, Epidemiology , Baltimore , United States of America
| |
Collapse
|
6
|
Matsushita K, Kaptoge S, Hageman SHJ, Visseren FLJ, Pennells L, Coresh J. Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The 2021 ESC guideline on cardiovascular disease (CVD) prevention qualitatively categorizes moderate and severe chronic kidney disease (CKD) as high and very-high CVD risk status regardless of other factors like age and does not include estimated glomerular filtration rate (eGFR) and albuminuria in its algorithms, SCORE2 and SCORE2-OP, to predict CVD risk.
Purpose
To develop and validate an “Add-on” to incorporate CKD measures into these algorithms, using a validated approach.
Methods
In 3,054,840 participants from 34 datasets, we developed three Add-ons (eGFR only, eGFR + urinary albumin-to-creatinine ratio [ACR] [the primary Add-on], and eGFR + dipstick proteinuria) for SCORE2 and SCORE2-OP. We validated c-statistics and net reclassification improvement (NRI), accounting for competing risk of non-CVD death, in 5,995,067 participants from 33 different datasets.
Results
In the target population of SCORE2 and SCORE2-OP without diabetes, the CKD Add-on (eGFR only) and CKD Add-on (eGFR + ACR) improved c-statistic by 0.006 (95% CI 0.005–0.008) and 0.018 (0.012–0.024), respectively, for SCORE2 and 0.012 (0.009–0.015) and 0.023 (0.013–0.032), respectively, for SCORE2-OP. Similar results were seen when we included individuals with diabetes and tested the CKD Add-on (eGFR + dipstick). In 57,485 European participants with CKD, SCORE2 or SCORE2-OP with a CKD Add-on showed a significant NRI (e.g., 0.100 [0.062–0.138] for SCORE2) compared to the qualitative approach in the ESC guideline.
Conclusion
Our Add-ons with CKD measures improved CVD risk prediction beyond SCORE2 and SCORE2-OP. This approach will help clinicians and patients with CKD refine risk prediction and further personalize preventive therapies for CVD.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): US National Kidney Foundation funding as well as US NIDDK
Collapse
Affiliation(s)
- K Matsushita
- Johns Hopkins Bloomberg School of Public Health , Baltimore , United States of America
| | - S Kaptoge
- University of Cambridge, Department of Public Health and Primary Care , Cambridge , United Kingdom
| | - S H J Hageman
- University Medical Center Utrecht, Department of Vascular Medicine , Utrecht , The Netherlands
| | - F L J Visseren
- University Medical Center Utrecht, Department of Vascular Medicine , Utrecht , The Netherlands
| | - L Pennells
- University of Cambridge, Department of Public Health and Primary Care , Cambridge , United Kingdom
| | - J Coresh
- Johns Hopkins Bloomberg School of Public Health , Baltimore , United States of America
| |
Collapse
|
7
|
Hmadeh S, Trimaille A, Matsushita K, Zobairi F, Sato C, Kindo M, Hoang T, Marchandot B, Toti F, Zibara K, Hamade E, Schini Kerth V, Kauffenstein G, Morel O. Enrichment in procoagulant microparticles in calcified human aortic valve – role in valvular endothelium alterations and enhanced thrombogenicity. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Aortic stenosis (AS) is characterized by endothelial dysfunction (ED), inflammatory cell infiltration, myofibroblastic and osteoblastic differentiation. Subclinical leaflet thrombosis was recently linked to higher rates of stroke and transient ischemic attack after transcatheter aortic valve implantation (TAVI). Procoagulant microparticles (MPs) are associated with ED, inflammation and clot formation. There is limited evidence regarding intra-valvular MPs content and their potential biological effects. This question is particularly relevant in TAVI in which the residing native valve could constitute a source of thrombotic activity enhancing leaflet thrombosis and valve dysfunction.
Purpose
Therefore, we hypothesized that MPs trapped within the native aortic valve contribute to valvular dysfunction including enhanced thrombogenicity.
Methods
Human valves were collected from patients undergoing surgical valve replacement for AS or aortic insufficiency (AI). Pro-thrombotic, pro-inflammatory, and ED markers were identified in the calcified vs non-calcified part of the valves by Western-blot. Calcium content was measured through colorimetric method. MPs were extracted from human pathological valves, and quantified through their prothrombinase activity. Primary cultures of porcine valvular endothelial cells (VEC) were treated with the MPs (10 nmol/L) or thrombin (1U/ml) for 24hrs. Phenotypic change was appreciated through gene expression pattern assessed by RT-qPCR. IL-8 secretion was measured by ELISA.
Results
The phenotype of the AS valve was characterized through increased expression of thrombogenic (tissue factor, thrombomodulin, PAI-1), adhesive (VCAM-1, ICAM-1) and inflammatory (COX-1, COX-2) molecules in the calcified part of the valve. Moreover, MPs content was increased in the calcified vs non-calcified part of the valve or AI valves. MPs levels was correlated with valvular calcium content (R=0.3862: p<0.001). Tissue factor was increased in MPs extracted from AS vs AI. The biological effect of MPs was tested on VEC in-vitro. Results showed dramatic increase in expression of inflammatory cytokines (CXCL10, CCL11, CXCL8, MCP1) adhesion molecules (VCAM-1, ICAM-1, SELP, SELE) and proangiogenic factors (VEGFR2, ANGPTL4) in VEC exposed to MPs (24h) from AS vs AI. Enhanced secretory phenotype was evidenced through IL-8 determination in the supernatant of VEC stimulated with MPs from AS valve.
Conclusion
Calcified aortic valve is a potent reservoir of MPs, acting as a pro-thrombogenic source per se and promoting a switch of VEC phenotype toward prothrombotic, proinflammatory and proangiogenic pattern. These data suggest that MPs released from the native valve constitute an important source of mediators involved in enhanced thrombogenicity and valvular remodeling.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): GERCA-Groupe Etudes Reali Commercia Avignon
Collapse
Affiliation(s)
- S Hmadeh
- INSERM, UMR 1260 , Strasbourg , France
| | - A Trimaille
- Civil Hospital/ Nouvel Hopital Civil , Strasbourg , France
| | | | - F Zobairi
- INSERM, UMR 1260 , Strasbourg , France
| | - C Sato
- INSERM, UMR 1260 , Strasbourg , France
| | - M Kindo
- Civil Hospital/ Nouvel Hopital Civil , Strasbourg , France
| | - T Hoang
- Civil Hospital/ Nouvel Hopital Civil , Strasbourg , France
| | - B Marchandot
- Civil Hospital/ Nouvel Hopital Civil , Strasbourg , France
| | - F Toti
- INSERM, UMR 1260 , Strasbourg , France
| | - K Zibara
- Lebanese University , Beirut , Lebanon
| | - E Hamade
- Lebanese University , Beirut , Lebanon
| | | | | | - O Morel
- Civil Hospital/ Nouvel Hopital Civil , Strasbourg , France
| |
Collapse
|
8
|
Gong DS, Mroueh A, Matsushita K, Fakih W, Auger C, Oak MH, Pieper MP, Morel O, Epailly E, Schini-Kerth V. SGLT1/2 expression in the heart of transplanted patients is associated with inflammatory induction of oxidative stress: potential protective effect of SGLT2 inhibitors. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.3007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Heart transplantation is a life-saving surgical procedure for patients with end-stage cardiac dysfunction, however, such procedures are usually at risk of rejection due to acute inflammatory activation. While such inflammatory induction leaves the newly transplanted heart at risk of functional and structural remodeling subsequent to oxidative damage, current anti-inflammatory treatment options expose the patient to an elevated risk for adverse reactions in addition to absence of cardio-protective effects. Therefore, novel therapies with anti-inflammatory and cardio-protective dual effects are needed. Recently, our group has reported that low-grade inflammation is associated with upregulation of SGLT1/2 in arteries of human with cardiovascular diseases. Yet, the role and function of SGLT2 in human cardiac tissue remains poorly understood.
Aim
This study focuses on the expression pattern of SGLT1/2 in cardiac biopsies of heart transplanted patients and aim to identifying their functional impact.
Methods
Routine endomyocardial Biopsies (23) were performed for the detection of acute rejection heart transplanted patients (less than 2 years) at our University Hospital. Gene expression levels were assessed using RT-qPCR, the in situ tissue localization of proteins by immunofluorescence staining, and the level of oxidative stress by dihydroethidium staining.
Results
Gene expression analysis revealed strong inflammatory reaction in 5 samples indicated by at least 20-fold higher levels of mRNA of IL1B, IL6, TNFA and CD68 compared to the other 18 samples and concomitant with high expression levels of SLC5A1, SLC5A2, AT1R, CYBA, NCF1, ICAM1, VCAM1, MMP2, MMP9 and TGFB1 in contrast to low levels of NOS3. In addition, increased levels of oxidative stress were observed in the same biopsies, which were diminished by the antioxidant N-acetylcysteine (NAC), NADPH oxidase inhibitor (VAS-2870), TNF-α receptor neutralizing antibody (infliximab), ACE inhibitor (perindoprilat), AT1R antagonist (losartan), dual SGLT1/2 inhibitor (sotagliflozin) and selective SGLT2 inhibitor (empagliflozin) with inhibitory effects reaching up to 80%. Immunofluorescence staining indicated signals for nitro-tyrosine, TNF-alpha, SGLT1 and 2 in several samples.
Conclusion
These findings indicate that both isoforms SGLT1 and SGLT2 are expressed in the transplanted human heart and suggest a pattern of expression associated with pro-inflammatory response. They further indicate a potential protective effect of SGLT2 inhibitors in transplanted hearts through mitigating oxidative stress and hence providing a possible novel therapy for heart transplantation recipients to preserve the heart function.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Boehringer Ingelheim Pharma GmbH & Co. KG
Collapse
Affiliation(s)
- D S Gong
- University of Strasbourg, INSERM UMR 1260, Centre de Recherche en Biomedicine de Strasbourg , Strasbourg , France
| | - A Mroueh
- University of Strasbourg, INSERM UMR 1260, Centre de Recherche en Biomedicine de Strasbourg , Strasbourg , France
| | - K Matsushita
- University of Strasbourg, INSERM UMR 1260, Centre de Recherche en Biomedicine de Strasbourg , Strasbourg , France
| | - W Fakih
- University of Strasbourg, INSERM UMR 1260, Centre de Recherche en Biomedicine de Strasbourg , Strasbourg , France
| | - C Auger
- University of Strasbourg, INSERM UMR 1260, Centre de Recherche en Biomedicine de Strasbourg , Strasbourg , France
| | - M H Oak
- Mokpo National University, College of Pharmacy , Mokpo , Korea (Republic of)
| | - M P Pieper
- Boehringer Ingelheim Pharma GmbH and Co. KG , Biberach , Germany
| | - O Morel
- Civil Hospital/ Nouvel Hopital Civil, INSERM UMR 1260, Centre de Recherche en Biomedicine de Strasbourg , Strasbourg , France
| | - E Epailly
- Civil Hospital/ Nouvel Hopital Civil, Department of Cardiology , Strasbourg , France
| | - V Schini-Kerth
- University of Strasbourg, INSERM UMR 1260, Centre de Recherche en Biomedicine de Strasbourg , Strasbourg , France
| |
Collapse
|
9
|
Hageman SHJ, Pennells L, Pajouheshnia R, Tillmann T, Blaha MJ, McClelland RL, Matsushita K, Nambi V, Van Der Schouw YT, Verschuren WMM, Lehmann N, Jockel KH, Di Angelantonio E, Visseren FLJ, Dorresteijn JAN. The value of additional risk factors for improving 10-year cardiovascular risk prediction in apparently healthy people. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
In clinical practice, factors known to be associated with cardiovascular disease (CVD) like albuminuria, education level, or coronary calcium score are not directly incorporated in cardiovascular risk prediction models. The aim of the current study was to quantify the added value of potential risk modifying characteristics when added to the SCORE2 algorithm for individuals without diabetes mellitus (DM) or prior CVD.
Methods and results
Individuals without previous CVD or DM were included from the ARIC, MESA, EPIC-NL and HNR studies (n=46,285) in whom 2,177 CVD events and 2,062 non-cardiovascular deaths were observed over exactly 10.0 years of follow-up. The effect of each possible risk modifying characteristic was derived using Fine and Gray models that included an offset term for the SCORE2 linear predictor. The risk modifying characteristics were applied to individual predictions using the “naïve approach”, which modifies predicted risks based on the population prevalence and the SHR of the relevant predictor. Subdistribution hazard ratios are presented in the table. External validation was performed in the CPRD cohort (UK, n=518,015, 12,675 CVD events). In the external validation, adjustment of SCORE2 predicted risks with both single and with all available risk modifiers did not negatively affect calibration (see figure) and led to a modest increase in discrimination (C-index 0.742 [95% CI 0.737–0.746] versus unimproved SCORE2 risk C-index 0.737 [95% CI 0.732–0.741]). The net reclassification index or adding all these predictors was +0.032 (95% CI 0.025; 0.028) for future events and −0.008 (95% CI −0.009; −0.007) for future non-events. The coronary calcium score was found to the single strongest added predictor.
Interpretation
The current analysis presents a method on how to integrate possible risk modifying characteristics that are not included in existing CVD risk models for the prediction of CVD event risk in apparently healthy people. This flexible methodology improves the accuracy of predicted risks and increases applicability of prediction models for individuals with additional risk known modifiers
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- S H J Hageman
- University Medical Center Utrecht, Department of vascular medicine , Utrecht , The Netherlands
| | - L Pennells
- University of Cambridge, Department of Public Health and Primary Care , Cambridge , United Kingdom
| | - R Pajouheshnia
- Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology , Utrecht , The Netherlands
| | - T Tillmann
- University of Tartu, Institute of Family Medicine and Public Health , Tartu , Estonia
| | - M J Blaha
- The Johns Hopkins Hospital, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease , Baltimore , United States of America
| | - R L McClelland
- University of Washington, Department of Biostatistics , Seattle , United States of America
| | - K Matsushita
- Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology , Baltimore , United States of America
| | - V Nambi
- Baylor College of Medicine, Department of Medicine , Houston , United States of America
| | - Y T Van Der Schouw
- University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care , Utrecht , The Netherlands
| | - W M M Verschuren
- National Institute for Public Health and the Environment (RIVM), Centre for Nutrition, Prevention and Health Services , Bilthoven , The Netherlands
| | - N Lehmann
- University hospital Essen, Institute for Medical Informatics, Biometry and Epidemiology , Essen , Germany
| | - K H Jockel
- University hospital Essen, Institute for Medical Informatics, Biometry and Epidemiology , Essen , Germany
| | - E Di Angelantonio
- University of Cambridge, Department of Public Health and Primary Care , Cambridge , United Kingdom
| | - F L J Visseren
- University Medical Center Utrecht, Department of vascular medicine , Utrecht , The Netherlands
| | - J A N Dorresteijn
- University Medical Center Utrecht, Department of vascular medicine , Utrecht , The Netherlands
| |
Collapse
|
10
|
Takashio S, Morioka M, Fujiyama A, Oike F, Hanatani S, Usuku H, Yamamoto E, Matsushita K, Tsujita K. Clinical characteristics, patient selection and clinical outcomes of tafamidis treatment in transthyretin amyloidosis cardiomyopathy. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Tafamidis is a stabilizer of transthyretin, specifically designed to decrease or prevent amyloidogenesis, and improves prognosis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). However, clinical coarse, selection of appropriate patients and monitoring therapeutic effect of tafamidis remained unclear.
Purpose
The aim of this study was to clarify the patients' characteristics, clinical coarse, and clinical outcomes of tafamidis in patients with ATTR-CM and to evaluate prognostic factors and changes in clinical data over time.
Methods
We evaluated consecutive 180 patients with ATTR-CM considering tafamids treatment. A total of 107 patients had tafamidis treatment (tafamidis treatment group) and 65 patients did not treat with tafamidis (treatment naïve group). The remaining 8 patients were preclinical. Clinical data were obtained at the consideration of tafamidis treatment. We divided the following the cut-off values of high-sensitivity cardiac troponin T (hs-cTnT); >0.05 ng/mL, B-type natriuretic peptide (BNP); >250 pg/ml, and estimated glomerular filtration rate (eGFR); <45 mL/min/1.73 m2 and calculated the score by adding 1 point if increased or decreased by more than the cut-off value. We divided patients into a low score group (0–1 point) and high score group (2–3 points).
Results
All of study patients in the tafamidis treatment group were wild-type ATTR-CM. Compared to tafamidis treatment group, tafamidis naïve group were significantly older (75.6±5.3 vs. 82.8±4.6 years; p<0.01), female dominant (8% vs. 28%; p<0.01), increased BNP levels (median 209 vs 306 pg/ml; p<0.01), and lower haemoglobin levels (14.1±1.8 vs. 12.4±1.8 g/dl; p<0.01). Tafamidis treatment group was significantly favourable clinical outcomes competed to treatment naïve group (p<0.05; log rank test). According to multivariate logistic regression analysis, prior heart failure hospitalization (hazard ratio [HR]: 5.93, 95% confidence interval [CI]: 1.25–28.03, p=0.03) and high score group (HR: 1.56, 95% CI: 0.37–7.25; <0.01) were the significant poor prognostic factors in tafamids treatment group. Among tafamidis treatment group, Hs-cTnT levels were significantly decreased after 12 months tafamidis treatment (0.055 [0.037–0.082] vs. 0.044 [0.033–0.077]; p<0.01) instead of no significant differences in BNP and significant decline of eGFR levels. There were no significant changes over time in the echocardiographic parameters after 12 months, and native T1 and extracellular volume fraction obtained by cardiac magnetic resonance in a limited number of patients.
Conclusion
The prognosis of ATTR-CM patients treated with tafamidis was favorable compared to tafamidis naïve group. Patient stratification combined with biomarkers predicted favorable prognosis in patients with tafamidis treatment. Hs-cTnT may be a useful maker for evaluating the therapeutic effect by tafamidis.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- S Takashio
- Kumamoto University Hospital , Kumamoto , Japan
| | - M Morioka
- Kumamoto University Hospital , Kumamoto , Japan
| | - A Fujiyama
- Kumamoto University Hospital , Kumamoto , Japan
| | - F Oike
- Kumamoto University Hospital , Kumamoto , Japan
| | - S Hanatani
- Kumamoto University Hospital , Kumamoto , Japan
| | - H Usuku
- Kumamoto University Hospital , Kumamoto , Japan
| | - E Yamamoto
- Kumamoto University Hospital , Kumamoto , Japan
| | | | - K Tsujita
- Kumamoto University Hospital , Kumamoto , Japan
| |
Collapse
|
11
|
Morioka M, Takashio S, Fujiyama H, Oike F, Hanatani S, Usuku H, Yamamoto E, Matsushita K, Tsujita K. Change in echocardiography in patients with transthyretin amyloid cardiomyopathy with tafamidis treatment. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and infiltrative disease caused by the deposition of insoluble transthyretin (TTR) amyloid fibrils in the myocardium, which leads to cardiomyopathy characterized by increased ventricular wall thickness and diastolic dysfunction. TTR amyloid fibrils are performed by dissociation of the tetrameric TTR into monomers and misfolding and misassemble into insoluble fibrils. Tafamidis stabilizes the tetramers and inhibits the TTR monomerization, leads to inhibit the formation and deposition of TTR fibril. Clinical trials suggested tafamidis could improve prognosis by slowing the progression of amyloidosis. Evaluation of serial measurement echocardiographic findings by tafamidis treatment is important, but these data has not been fully revealed.
Purpose
The aim of study was to evaluate the change of echocardiographic parameter in patients with ATTR-CM received tafamidis for 12 months. Especially in strain echocardiogram, global longitudinal strain (GLS) has reported to be associated with prognosis, and apical sparing pattern, which longitudinal strain (LS) in the basal and middle segments is more severely impaired than the apical segments, is specific finding in ATTR-CM.
Method
Echocardiographic findings before and 12 months were compared in 68 patients with ATTR-CM who started a new prescription of tafamidis and 18 tafamidis naïve patients with ATTR-CM patients who underwent echocardiography annually prior to the approval of tafamidis.
Result
Among tafamidis treatment group, echocardiographic parameters were not significant changes before and after 12 months tafamidis treatment [left ventricular ejection fraction (LVEF): 49.6±10.6% vs. LVEF: 49.9±10.7% (p=0.767), interventricular septum diameter (IVSd):16.0±2.3mm vs 15.7±2.1mm (p=0.241), left ventricular posterior wall diameter (LVPWd):16.1±2.5mm vs 16.1±2.5mm (p=0.964), GLS: −8.4±2.7% vs −8.2±2.8% (p=0.419), LS at base: −4.6±2.6% vs −4.2±2.4% (p=0.291), LS at middle: −6.9±3.6% vs −6.9±2.8% (p=0.922), LS at apical:-12.7±4.2% vs −12.4±4.4% (p=0.615). Among tafamidis naïve group, these parameters remained almost unchanged in 12 months as well, except for GLS and LS at apical. LS at apical showed a significant impairment. [LVEF: 53.8±9.2% vs 51.7±9.3% (p=0.244), IVSd: 15.5±2.3mm vs 16.0±1.8mm (p=0.321), LVPWd: 15.4±2.3mm vs 15.9±2.3mm (p=0.267), GLS: −10.4±2.4% vs −9.0±2.9% (p=0.065), LS at base: −5.0±2.7% vs −5.1±2.9% (p=0.865), LS at middle: −8.9±3.1% vs −8.5±3.5% (p=0.565), LS at apical: −15.4±4.0% vs −12.6±4.4% (p=0.02); Table 1]
Conclusion
We evaluated changes in echocardiographic findings with tafamidis treatment for 12 months. The echocardiographic parameters did not change over the course of 12 months, but the decrease in LS at apex observed in the tafamidis naïve group.Segmental LS could reflect a slight progression of cardiac amyloidosis and the short-term effects of tafamidis.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- M Morioka
- Kumamoto University Hospital , Kumamoto , Japan
| | - S Takashio
- Kumamoto University Hospital , Kumamoto , Japan
| | - H Fujiyama
- Kumamoto University Hospital , Kumamoto , Japan
| | - F Oike
- Kumamoto University Hospital , Kumamoto , Japan
| | - S Hanatani
- Kumamoto University Hospital , Kumamoto , Japan
| | - H Usuku
- Kumamoto University Hospital , Kumamoto , Japan
| | - E Yamamoto
- Kumamoto University Hospital , Kumamoto , Japan
| | | | - K Tsujita
- Kumamoto University Hospital , Kumamoto , Japan
| |
Collapse
|
12
|
Matsushita K, Kobayashi S, Akita H, Konno M, Asai A, Noda T, Iwagami Y, Asaoka T, Gotoh K, Mori M, Doki Y, Eguchi H, Ishii H. Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. Cancer Rep (Hoboken) 2022; 5:e1582. [PMID: 34821071 PMCID: PMC9575502 DOI: 10.1002/cnr2.1582] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 08/31/2021] [Accepted: 10/12/2021] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Pancreatic ductal adenocarcinoma is one of the most aggressive malignancies, and often involves invasion and distant metastasis from the early tumor stages. Myosin II reportedly plays a key role in regulating tumor progression and metastasis. AIMS We examined whether myosin regulatory light polypeptide 9 (MYL9) regulates cancer cell proliferation. METHODS AND RESULTS To investigate the expression pattern and clinical significance of MYL9 in pancreatic ductal adenocarcinoma, we performed immunohistochemical analysis of samples collected from 101 patients with pancreatic ductal adenocarcinoma. The expression of MYL9 was investigated to evaluate its functional role and contribution to proliferation and apoptosis in pancreatic ductal adenocarcinoma cells in vitro. The results showed that MYL9 was predominantly expressed in the cytoplasm and membrane of pancreatic ductal adenocarcinoma cells. Multivariate analysis indicated that MYL9 acted as an independent prognostic factor for overall survival and distant metastasis-free survival. MYL9 expression was strongly associated with malignancy in in vitro analyses, including proliferation and anti-apoptotic activities. CONCLUSIONS Our findings suggest that MYL9 is an independent prognostic factor of pancreatic ductal adenocarcinoma. MYL9 is a crucial biomarker and potential therapeutic target for pancreatic ductal adenocarcinoma.
Collapse
Affiliation(s)
- Katsunori Matsushita
- Department of Gastroenterological SurgeryGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
- Center of Medical Innovation and Translational ResearchGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
| | - Shogo Kobayashi
- Department of Gastroenterological SurgeryGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
| | - Hirofumi Akita
- Department of Gastroenterological SurgeryGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
| | - Masamitsu Konno
- Department of Gastroenterological SurgeryGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
- Center of Medical Innovation and Translational ResearchGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
| | - Ayumu Asai
- Center of Medical Innovation and Translational ResearchGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
- Artificial Intelligence Research CenterThe Institute of Scientific and Industrial Research, Osaka UniversityIbarakiOsakaJapan
- Institute of Scientific and Industrial ResearchOsaka UniversityIbarakiOsakaJapan
| | - Takehiro Noda
- Department of Gastroenterological SurgeryGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
| | - Yoshifumi Iwagami
- Department of Gastroenterological SurgeryGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
| | - Tadafumi Asaoka
- Department of Gastroenterological SurgeryGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
| | - Kunihito Gotoh
- Department of Gastroenterological SurgeryGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
| | - Masaki Mori
- Department of Gastroenterological SurgeryGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
- Department of Surgery and ScienceGraduate School of Medical Sciences, Kyushu UniversityFukuokaJapan
| | - Yuichiro Doki
- Department of Gastroenterological SurgeryGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
- Center of Medical Innovation and Translational ResearchGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
| | - Hidetoshi Eguchi
- Department of Gastroenterological SurgeryGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
- Center of Medical Innovation and Translational ResearchGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
| | - Hideshi Ishii
- Center of Medical Innovation and Translational ResearchGraduate School of Medicine, Osaka UniversitySuitaOsakaJapan
| |
Collapse
|
13
|
Martinez JF, Mulhall JP, Deveci S, Matsushita K, Torremade J, Salter CA. Testosterone (T) challenge in men post-radical prostatectomy (RP) with profoundly low testosterone. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.03.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
Flores Martinez J, Mulhall JP, Deveci S, Matsushita K, Torremade J, Salter CA. Testosterone (T) Challenge in Men Post-Radical Prostatectomy (RP) with Profoundly Low Testosterone. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.01.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
15
|
Matsushita K, Marchandot B, Hess S, Kibler M, Sato C, Heger J, Truong D, Trimaille A, Sattler L, Grunebaum L, Reydel Dedieu A, Jesel L, Ohlmann P, Morel O. Primary hemostatic disorders drive early and late major bleedings of patients with atrial fibrillation after transcatheter aortic valve replacement. Archives of Cardiovascular Diseases Supplements 2022. [DOI: 10.1016/j.acvdsp.2021.09.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
16
|
Trimaille A, Marchandot B, Oulehri W, Carmona A, Vollmer O, Poindron V, Matsushita K, Sattler L, Grunebaum L, Korganow A, Schini-Kerth V, Morel O. Transient endothelial injury and release of lupus anticoagulant in COVID-19. Archives of Cardiovascular Diseases Supplements 2022. [PMCID: PMC8710966 DOI: 10.1016/j.acvdsp.2021.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Introduction Purpose Methods Results Conclusions
Collapse
|
17
|
Trimaille A, Matsushita K, Marchandot B, Carmona A, Hess S, Kibler M, Heger J, Reydel A, Sattler L, Grunebaum L, Jesel L, Ohlmann P, Morel O. Baseline mean platelet volume is a strong predictor of major and life-threatening bleedings after transcatheter aortic valve replacement. Archives of Cardiovascular Diseases Supplements 2022. [DOI: 10.1016/j.acvdsp.2021.09.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Matsushita K, Hagihara K, Motoki Y, Sakisaka H, Akiyama Y, Nakaguchi K, Doi S. [A Case of Primary Jejunal Cancer Treated with Laparoscopic Jejunectomy with Appearance of Ileus]. Gan To Kagaku Ryoho 2021; 48:1622-1624. [PMID: 35046276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
An 83-year-old man visited our hospital for vomiting. Chest-abdominal computed tomography(CT)revealed that a tumor whose inside was imaged in the jejunum about 15 cm after leaving the Treitz ligament was pointed out, and dilation of the oral intestinal tract of the tumor was observed. Upper gastrointestinal endoscopy showed a type 3 circumferential tumor at the jejunum. He was diagnosed with obstructive ileus due to jejunal cancer. Laparoscopic-assisted partial jejunal resection was performed. Although the patient was followed up without chemotherapy, CT showed multiple lung and liver metastases and a mass lesion was found in the right entire chest, and a biopsy revealed skin metastasis 6 months after the operation. The patient is being followed up 10 months after surgery, there is no progression of liver, lung, and skin metastasis.
Collapse
|
19
|
Kuyama N, Kaikita K, Mitsuse T, Fujisue K, Nakanishi N, Tabata N, Yamanaga K, Sueta D, Kanazawa H, Takashio S, Araki S, Arima Y, Yamamoto E, Matsushita K, Tsujita K. Total thrombus-formation analysis system (T-TAS) can predict target lesion revascularization in patients undergoing endovascular therapy for critical limb ischemia. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Despite of the development of endovascular therapy (EVT), the frequency of target lesion revascularization (TLR) after EVT in patients with critical limb ischemia (CLI) is still high. Recent histrogical study suggested the possibility of thromboembolic phenomenon in the development of CLI; however, there is few monitoring system of total thrombogenicity in perioperative period of EVT in CLI patients. The total thrombus-formation analysis system (T-TAS), a novel system for quantitatively analyzing thrombus formation using microchips with thrombogenic surfaces (collagen plus tissue factor, atheroma [AR]-chip), is validated and can evaluate the total thrombogenicity.
Purpose
To investigate the utility of T-TAS parameters in predicting TLR after EVT in CLI patients.
Methods
We analyzed 27 CLI patients (45 lesions; aortoiliac 20%, femoropopliteal 40%, infrapopliteal 40%) who underwent EVT at our institution between January 2018 and December 2020. Patients undergoing hemodialysis were excluded. Blood sample was collected on the day of EVT and was used in T-TAS to compute the thrombus formation area under the curve (AUC; AUC for the first 30 minutes for AR tested at flow rate of 10 lL/min [AR10-AUC30]). We investigated the relationship between the AR10-AUC30 level and the occurrence of clinically-driven TLR, and the predictors of TLR among CLI patients.
Results
Study population had a mean age of 77 years, and 56% were male. During the follow-up period (mean 1.0±0.7 years), 11 lesions (24%) required clinically-driven TLR. The AR10-AUC30 level was significantly higher in patients requiring TLR than those without TLR (1783±121 vs. 1587±205; p<0.01). The frequency of TLR significantly increased in association with a tertile of the AR10-AUC30 level (Figure 1, p for trend=0.003). As shown in Figure 2, univariate logistic regression analysis demonstrated male sex and the third tertile of the AR10-AUC30 level compared to its first or second tertiles were significantly associated with TLR in patients with CLI, whereas platelet count, PT-INR, APTT, and atherosclerotic risk factors including glycated hemoglobin, low-density lipoprotein cholesterol, and renal function were not. Multivariate logistic regression analysis also revealed that the AR10-AUC30 level ≥1707 (=its third tertile) as an independent predictor for TLR, even after adjusted by age and sex (OR=6.28, 95% CI=1.18–33.3, p=0.03).
Conclusions
In patients with CLI, the AR10-AUC30 level measured by the T-TAS may be a potential predictor to identify the high-risk patients requiring TLR after EVT. This finding suggests the hypercoagulability in CLI patients and that an anticoagulant agent following EVT may be useful in preventing a restenosis in CLI patients. Further study with a larger sample size is warranted to validate this finding.
Funding Acknowledgement
Type of funding sources: None. Figure 1Figure 2
Collapse
Affiliation(s)
- N Kuyama
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - K Kaikita
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - T Mitsuse
- Arao Municipal Hospital, Cardiology, Arao, Japan
| | - K Fujisue
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - N Nakanishi
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - N Tabata
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - K Yamanaga
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - D Sueta
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - H Kanazawa
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - S Takashio
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - S Araki
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - Y Arima
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - E Yamamoto
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - K Matsushita
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| | - K Tsujita
- Kumamoto University, Cardiovascular medicine, Kumamoto, Japan
| |
Collapse
|
20
|
Matsushita K, Marchandot B, Hess S, Kibler M, Sato C, Heger J, Truong DP, Trimaille A, Sattler L, Grunebaum L, Reydel A, Jesel L, Ohlmann P, Morel O. Primary hemostatic disorders drive early and late major bleedings of patients with atrial fibrillation after transcatheter aortic valve replacement. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Patients with atrial fibrillation (AF) are likely to have multiple co-morbidities and receive anticoagulants after TAVR, which lead to a poor prognosis including bleeding events. Closure time adenosine diphosphate (CT-ADP) is a primary hemostasis point-of-care test used as a surrogate marker of high molecular weight (HMW) multimers defect of Von Willebrand factor (VWF). Our prior studies suggest that prolongation of CT-ADP (>180 seconds) after TAVR is a major determinant of early and late major/life-threatening bleeding complications (MLBCs).
Purpose
To evaluate the impact of post-procedural CT-ADP >180sec on bleeding events in AF patients.
Methods
We included 878 patients from our prospective TAVR registry between 2010 and 2019. Bleeding complications were assessed according to the VARC-2 (Valve Academic Research Consortium-2) criteria. Major adverse cardiac and cerebrovascular events (MACCE) was defined as a composite of all-cause death, myocardial infarction, stroke, and heart failure hospitalization within 1-year after TAVR. Ongoing primary haemostasis disorder was defined by post-procedure CT-ADP >180sec. Primary endpoint was the occurrence of MLBCs during the first year and the second endpoint was 1-year MACCE.
Results
Patients with AF had a higher incidence of all-cause mortality (15% vs. 8%, p=0.002), MACCE (29% vs. 20%, p=0.002), and MLBCs (20% vs. 12%, p=0.001) within 1-year compared to non-AF patients. When the cohort was split into 4 subgroups according to AF and CT-ADP >180sec, patients with AF and CT-ADP >180sec had the highest risk of MLBCs (log-rank test; p<0.001) (Figure). Multivariate Cox regression analysis confirmed that the patients with AF and CT-ADP >180sec had 4.6-fold higher risk of MLBCs within 1 year compared to non-AF patients with CT-ADP ≤180sec (hazard ratio: 4.60; 95% confidence interval: 2.18 - 9.68; p<0.001).
Conclusion
Among TAVR patients, AF with post-procedural CT-ADP >180 sec was identified as a strong independent predictor of MLBCs at 1-year follow-up. Our study suggest that persistent primary haemostasis disorders contribute to a higher risk of bleeding events particularly in AF patients and may be considered for a tailored and risk-adjusted antithrombotic therapy after TAVR.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Dr Matsushita received a grant from Edwards Lifesciences.
Collapse
Affiliation(s)
- K Matsushita
- University Hospital of Strasbourg, Strasbourg, France
| | - B Marchandot
- University Hospital of Strasbourg, Strasbourg, France
| | - S Hess
- University Hospital of Strasbourg, Strasbourg, France
| | - M Kibler
- University Hospital of Strasbourg, Strasbourg, France
| | - C Sato
- University Hospital of Strasbourg, Strasbourg, France
| | - J Heger
- University Hospital of Strasbourg, Strasbourg, France
| | - D P Truong
- University Hospital of Strasbourg, Strasbourg, France
| | - A Trimaille
- University Hospital of Strasbourg, Strasbourg, France
| | - L Sattler
- University Hospital of Strasbourg, Strasbourg, France
| | - L Grunebaum
- University Hospital of Strasbourg, Strasbourg, France
| | - A Reydel
- University Hospital of Strasbourg, Strasbourg, France
| | - L Jesel
- University Hospital of Strasbourg, Strasbourg, France
| | - P Ohlmann
- University Hospital of Strasbourg, Strasbourg, France
| | - O Morel
- University Hospital of Strasbourg, Strasbourg, France
| |
Collapse
|
21
|
Morioka M, Takashio S, Nakashima N, Nishi M, Hirakawa K, Hanatani S, Usuku H, Yamamoto E, Matsushita K, Kaikita K, Tsujita K. Correlations between pathological deposition and non-invasive diagnostic modalities like 99mTc-PYP scintigraphy, cardiac magnetic resonance, GLS in patients with transthyretin cardiac amyloidosis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Although wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) was previously considered a rare disease, recent diagnostic imaging modalities have revealed that it is considerably underdiagnosed among elderly patients with heart failure. The severity of CM is thought to be related to the extent of amyloid deposition in heart.
99mTc-labeled pyrophosphate (99mTc-PYP) scintigraphy, cardiovascular magnetic resonance (CMR), global longitudinal strain (GLS) provide diagnostic and prognostic information in ATTRwt-CM. However, the relevance of these imaging modalities and their association with cardiac amyloid load has not been fully evaluated.
Purpose
The aim of study was to elucidate the associations between pathological amyloid load and cardiac retention evaluated by 99mTc-PYP scintigraphy, CMR, GLS in patients with ATTRwt-CM.
Method
Cardiac amyloid load was calculated as (amyloid deposition area/ total myocardium area)×100 using endomyocardial biopsy specimen. Cardiac retention was quantified by heart to contralateral (H/CL) ratio by 99mTc-PYP scintigraphy. Native T1 and extracellular volume (ECV) were obtained by CMR. GLS was analyzed using the 2D echo at the time of diagnosis.
Result
The mean cardiac amyloid load was 23.0±15.2% (n=57) and correlation with H/CL ratio (1.94±0.36 n=57), native T1 (1426.7±52.5 n=57), ECV (57.9±12.9 n=54), GLS (−9.1±2.4 n=57) were positive (r=0.375 p=0.004, r=0.496 r=0.304 p<0.001, r=0.304 p=0.025, r=0.473 p<0.001).
Conclusion
Increased cardiac amyloid load correlated with an increased 99mTc-PYP positivity, native T1, ECV, and an impaired GLS. These results suggest that imaging parameters may reflect histological and functional changes due to amyloid deposition in the myocardium.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- M Morioka
- Kumamoto University, Kumamoto, Japan
| | | | | | - M Nishi
- Kumamoto University, Kumamoto, Japan
| | | | | | - H Usuku
- Kumamoto University, Kumamoto, Japan
| | | | | | - K Kaikita
- Kumamoto University, Kumamoto, Japan
| | - K Tsujita
- Kumamoto University, Kumamoto, Japan
| |
Collapse
|
22
|
Takashio S, Morioka M, Nishi M, Nakashima N, Yamada T, Hirakawa K, Hanatani S, Usuku H, Yamamoto E, Matsushita K, Kaikita K, Tsujita K. Gender differences in clinical characteristics in wild-type transthyretin amyloidosis cardiomyopathy. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Aims
A significant male predominance has been reported in wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM). In other words, the female ATTRwt-CM may be overlooked and gender differences in ATTRwt-CM remain unclear. This study aims to examine gender differences in clinical characteristics and diagnostic approaches in ATTRwt-CM.
Methods and results
We retrospectively evaluated 171 consecutive ATTRwt-CM patients diagnosed at our university hospital between December 2002 and December 2020. Twenty-two patients (12%) were women. Women were significantly older at diagnosis (77.3 years vs. 83.3 years; P<0.001) and had a higher advanced New York Health Association functional class (2.23±0.70 vs. 2.57±0.81; P=0.04) than men. In echocardiography, mean interventricular septum diameter was less thick (15.8 mm vs. 14.5 mm; P=0.03) and ejection fraction was preserved (51.7% vs. 57.7%; P=0.08) in women. The mean heart-to-contralateral ratio obtained using 99mTc-labeled pyrophosphate (99mTc-PYP) was significantly lower in women than in men (1.89 vs. 1.64; P=0.001). There was no significant gender difference in high-sensitivity median cardiac troponin T levels at diagnosis (0.055 ng/mL vs. 0.069 ng/mL; P=0.30) or history of carpal tunnel syndrome (57% vs. 55%; P=0.93) and electrocardiograms findings. However, the median B-type natriuretic peptide level was significantly higher (254 pg/mL vs. 434 pg/mL; P=0.02) in women. Moderate to severe aortic stenosis was more frequently observed in women (5% vs. 50%; P<0.001). Histological (78% vs. 59%; P=0.07) and genetic confirmation (78% vs. 59%; P=0.003) of ATTRwt-CM were not performed in women.
Conclusion
Women with ATTRwt-CM were predominantly octogenarians, less hypertrophic, and had weaker cardiac uptake of the 99mTc-PYP tracer than men with ATTRwt-CM. These characteristics contribute to the underdiagnosis of ATTRwt-CM in women. The diagnosis of ATTRwt-CM in women is challenging. Therefore, we must be familiar with the clinical characteristics of women with ATTRwt-CM.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - M Morioka
- Kumamoto University, Kumamoto, Japan
| | - M Nishi
- Kumamoto University, Kumamoto, Japan
| | | | - T Yamada
- Kumamoto University, Kumamoto, Japan
| | | | | | - H Usuku
- Kumamoto University, Kumamoto, Japan
| | | | | | - K Kaikita
- Kumamoto University, Kumamoto, Japan
| | - K Tsujita
- Kumamoto University, Kumamoto, Japan
| |
Collapse
|
23
|
Park SH, Amissi S, Algara-Suarez P, Gong DS, Mroueh A, Belcastro E, Matsushita K, Bruckert C, Chaker AB, Jesel L, Ohlmann P, Morel O, Mazzucotelli JP, Schini-Kerth VB. Sodium-glucose co-transporter 1 and 2 expression in the mammary artery of patients with bypass surgery: role of the pro-inflammatory response and contribution to oxidative stress. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Selective sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown cardiovascular protection independently of glycemic control. Angiotensin II (Ang II) and H2O2 induced the expression of SGLT1 and 2 in cultured endothelial cells and isolated arteries to promote oxidative stress and endothelial dysfunction. However, the expression level and role of SGLT1 and 2 in human arteries remain poorly studied.
Purpose
This study examined the expression level of SGLT1 and 2 in the human internal mammary artery (IMA) obtained from bypass surgery patients, and, if so, determined the underlying mechanism and function.
Methods
IMAs were obtained from 40 bypass surgery patients (age 45 to 82). The expression level of target factors was assessed by Western blot analysis, immunofluorescence staining and RT-PCR, and the level of oxidative stress using dihydroethidium staining. Human kidney was used as a control tissue known to express SGLT1 and 2. Porcine coronary artery endothelial cells (CAEC) were cultured and studied at passage 1.
Results
Western blot analysis of 40 IMA samples indicated a high level of both SGLT1 and 2 in 16 and 17 IMAs, an intermediate level in 8 and 6 IMAs, and a low one in 16 and 17 IMAs, respectively. Immunofluorescence staining of IMA sections indicated that SGLT1 and 2 immunofluorescence signals were observed predominantly in the intima thickening and the media. The expression levels of SGLT1 and 2 were associated with p-p65 NF-kB signals but not angiotensin-converting enzyme (ACE), AT1R, MCP-1, VCAM-1. IMAs with a high expression level of SGLT1 and 2 had a high level of ROS throughout the arterial wall including the intima thickening and endothelium, which was inhibited by the antioxidant N-acetylcysteine, the ACE inhibitor perindoprilat, the AT1R antagonist losartan, and also by the dual SGLT1 and 2 inhibitor sotagliflozin and the selective SGLT2 inhibitor empagliflozin. Pro-inflammatory cytokines mRNA levels of IL-1β, TNF-α and IL-6 were detected in IMAs. Exposure of CAEC to either TNF-α, IL-1β or IL-6 caused a concentration-dependent upregulation of SGLT1 and 2.
Conclusion
The present findings indicate that SGLT1 and 2 expression is observed in some but not all IMAs of bypass surgery patients predominantly in the media, the intima thickening and the endothelium. High expression levels of SGLT1 and 2 are associated with NF-kB activation and oxidative stress that is prevented by a selective SGLT2 inhibitor and by a dual SGLT1/2 inhibitor. Since pro-inflammatory cytokines triggered SGLT1 and 2 expression in endothelial cells, the inflammatory burden of patients appears to be an important trigger regulating SGLT1/2 expression and the subsequent pro-oxidant response prompting pro-inflammatory and pro-thrombotic responses.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): This work was supported by an unrestricted research grant from Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Collapse
Affiliation(s)
- S H Park
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - S Amissi
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - P Algara-Suarez
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - D S Gong
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - A Mroueh
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - E Belcastro
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - K Matsushita
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - C Bruckert
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - A B Chaker
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - L Jesel
- University Hospital Strasbourg, Cardiology, Strasbourg, France
| | - P Ohlmann
- University Hospital Strasbourg, Cardiology, Strasbourg, France
| | - O Morel
- University Hospital Strasbourg, Cardiology, Strasbourg, France
| | | | - V B Schini-Kerth
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| |
Collapse
|
24
|
Matsushita K, Sato C, Bruckert C, Gong D, Hmadeh S, Fakih W, Remila L, Auger C, Jesel L, Ohlmann P, Kauffenstein G, Schini-Kerth V, Morel O. Protective effects of dapagliflozin on vascular remodeling in the carotid artery following balloon injury – potential role of angiotensin and purinergic signaling. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of cardiovascular events independently of glycemic control. The possibility that SGLT2 inhibitors improve endothelial regeneration and vascular restenosis is unknown.
Purpose
To examine whether dapagliflozin, a selective SGLT2 inhibitor, could prevent neointima thickening induced by balloon injury and, if so, to determine the underlying mechanisms. The effect of dapagliflozin was compared to that of losartan, an angiotensin type 1 receptor (AT1R) antagonist.
Methods
Saline, dapagliflozin (1.5 mg/kg/day), or losartan (30 mg/kg/day) were administered orally for 5 weeks to male Wistar rats. Balloon injury of the left carotid artery was performed 1 week after starting the treatment and sacrificed 4 weeks later. Vascular reactivity was assessed on left (injured) and right (healthy) carotid artery rings. The extent of neointima was assessed by histomorphometric analysis, changes of target factors by immunofluorescence, RT-qPCR and histochemistry.
Results
Dapagliflozin and losartan treatments reduced neointima thickening by 32% and 27%, respectively. Blunted contractile responses to phenylephrine and relaxations to acetylcholine and down-regulation of eNOS were observed in the injured artery. These effects were not modified by the dapagliflozin or the losartan treatments. RT-qPCR investigations indicated an increased in gene expression of inflammatory (IL-1beta, ITGAM, VCAM-1), oxidative (p47phox, p22phox) and fibrotic (TGF-beta1) markers and a decreased of eNOS in the injured carotid. However, these changes were not affected by the pharmacological treatments. By contrast, significant increased levels of AT1R angiotensin receptor and NTPDase1 (CD39) ectonucleotidase were observed in the restenotic carotid artery of the dapagliflozin group. Histochemical analysis evidenced important NTPDase1 activity in the neointima.
Conclusions
Dapagliflozin effectively reduced neointimal thickening. As the contribution of AT1R and P2Y2 ATP receptor in smooth muscle cell proliferation and neointima formation has been reported in the literature, the present data suggest that dapagliflozin prevents restenosis through interfering with angiotensin and/or extracellular nucleotides signaling. SGLT2 transporter represent potential new target for limiting vascular restenosis.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): This work was supported by AstraZeneca
Collapse
Affiliation(s)
- K Matsushita
- University of Strasbourg, UMR1260 INSERM, Nanomédecine Régénérative, Faculté de Pharmacie, Strasbourg, France
| | - C Sato
- University of Strasbourg, UMR1260 INSERM, Nanomédecine Régénérative, Faculté de Pharmacie, Strasbourg, France
| | - C Bruckert
- University of Strasbourg, UMR1260 INSERM, Nanomédecine Régénérative, Faculté de Pharmacie, Strasbourg, France
| | - D Gong
- University of Strasbourg, UMR1260 INSERM, Nanomédecine Régénérative, Faculté de Pharmacie, Strasbourg, France
| | - S Hmadeh
- University of Strasbourg, UMR1260 INSERM, Nanomédecine Régénérative, Faculté de Pharmacie, Strasbourg, France
| | - W Fakih
- University of Strasbourg, UMR1260 INSERM, Nanomédecine Régénérative, Faculté de Pharmacie, Strasbourg, France
| | - L Remila
- University of Strasbourg, UMR1260 INSERM, Nanomédecine Régénérative, Faculté de Pharmacie, Strasbourg, France
| | - C Auger
- University of Strasbourg, UMR1260 INSERM, Nanomédecine Régénérative, Faculté de Pharmacie, Strasbourg, France
| | - L Jesel
- University Hospital of Strasbourg, Strasbourg, France
| | - P Ohlmann
- University Hospital of Strasbourg, Strasbourg, France
| | - G Kauffenstein
- University of Strasbourg, UMR1260 INSERM, Nanomédecine Régénérative, Faculté de Pharmacie, Strasbourg, France
| | - V Schini-Kerth
- University of Strasbourg, UMR1260 INSERM, Nanomédecine Régénérative, Faculté de Pharmacie, Strasbourg, France
| | - O Morel
- University Hospital of Strasbourg, Strasbourg, France
| |
Collapse
|
25
|
Ooi K, Inoue N, Matsushita K, Yamaguchi H, Mikoya T, Kawashiri S, Tei K. Body Weight Loss After Orthognathic Surgery: Comparison Between Postoperative Intermaxillary Fixation with Metal Wire and Elastic Traction, Factors Related to Body Weight Loss. J Maxillofac Oral Surg 2021; 20:95-99. [PMID: 33584049 PMCID: PMC7855110 DOI: 10.1007/s12663-019-01318-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Accepted: 12/10/2019] [Indexed: 11/24/2022] Open
Abstract
INTRODUCTION The aim of this study was to compare body weight loss between postoperative intermaxillary fixation with metal wire and elastic traction and to investigate factors related to body weight loss after orthognathic surgery. MATERIALS AND METHODS Subjects were 59 patients with dentofacial deformity, comprising 31 patients treated with intermaxillary fixation (IMF) and 28 patients treated with elastic traction without IMF (ELT) just after surgery. Body weight loss was measured at 1 week (T1) and 2 weeks (T2) after surgery. Body weight loss was compared between IMF and ELT, and factors related to body weight loss were statistically analyzed. RESULTS Body weight loss ratio was significantly increased in IMF (2.6%) rather than in ELT (1.4%) at T1, but only tended to be increased in both groups at T2, showing no statistical difference. Body weight loss ratio was significantly increased at T2 compared to T1 in both groups. Body weight loss was significantly greater at T2 than at T1. CONCLUSION Both IMF and ELT cause body weight loss after orthognathic surgery, but IMF causes body weight loss earlier than ELT and increased early body weight loss increases continuous body weight loss after orthognathic surgery.
Collapse
Affiliation(s)
- K. Ooi
- Department of Oral and Maxillofacial Surgery, Graduate School of Medical Science, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641 Japan
- Oral and Maxillofacial Surgery, Department of Oral Patho-biological Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 Kita-ku, Sapporo, Hokkaido 060-8586 Japan
| | - N. Inoue
- Gerodontology, Department of Oral Health Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 Kita-ku, Sapporo, Hokkaido 060-8586 Japan
| | - K. Matsushita
- Oral and Maxillofacial Surgery, Department of Oral Patho-biological Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 Kita-ku, Sapporo, Hokkaido 060-8586 Japan
| | - H. Yamaguchi
- Oral and Maxillofacial Surgery, Department of Oral Patho-biological Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 Kita-ku, Sapporo, Hokkaido 060-8586 Japan
| | - T. Mikoya
- Oral and Maxillofacial Surgery, Department of Oral Patho-biological Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 Kita-ku, Sapporo, Hokkaido 060-8586 Japan
| | - S. Kawashiri
- Department of Oral and Maxillofacial Surgery, Graduate School of Medical Science, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641 Japan
| | - K. Tei
- Oral and Maxillofacial Surgery, Department of Oral Patho-biological Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 Kita-ku, Sapporo, Hokkaido 060-8586 Japan
| |
Collapse
|
26
|
Lachmet-Thébaud L, Marchandot B, Matsushita K, Sato C, Dagrenat C, Greciano S, De Poli F, Leddet P, Carmona A, Jimenez C, Heger J, Reydel A, Ohlmann P, Jesel L, Morel O. Residual systemic inflammatory burden is a major determinant of myocardial recovery and late cardiovascular outcome in Takotsubo patients. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2020.10.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Peillex M, Marchandot B, Matsushita K, Prinz E, Hess S, Reydel Dedieu A, Carmona A, Heger J, Trimaille A, Petit-Eisenmann H, Trinh A, Jesel L, Ohlmann P, Morel O. Acute kidney injury and Acute kidney recovery following TAVR: Conflicting results with regards to earlier studies. Archives of Cardiovascular Diseases Supplements 2021. [DOI: 10.1016/j.acvdsp.2020.10.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Ho C, Chih H, Garimella P, Matsushita K, Jansen S, Reid C. Prevalence of and Factors Associated With Peripheral Artery Disease in a Population With Chronic Kidney Disease in Australia: A Systematic Review and Meta-analysis. Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.06.418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
29
|
Carmona A, Marchandot B, Matsushita K, Curtiaud A, Elidrissi A, Trimaille A, Kibler M, Cardi T, Heger J, Hess S, Reydel A, Fafi-Kremer S, Schini-Kerth V, Jesel L, Ohlmann P, Morel O. Impact of Covid-19 infection in high-risk coronary patients. Archives of Cardiovascular Diseases Supplements 2021. [PMCID: PMC7803089 DOI: 10.1016/j.acvdsp.2020.10.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Background Methods Results Conclusions
Collapse
|
30
|
Trimaille A, Curtiaud A, Marchandot B, Matsushita K, Sato C, Leonard-Lorant I, Sattler L, Grunebaum L, Ohana M, Von Hunolstein J, Andres E, Goichot B, Danion F, Kaeuffer C, Poindron V, Ohlmann P, Jesel L, Morel O. Venous thromboembolism in non-critically ill patients with COVID-19 infection. Archives of Cardiovascular Diseases Supplements 2021. [PMCID: PMC7803092 DOI: 10.1016/j.acvdsp.2020.10.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Background Systemic coagulation activation and thrombotic complications are frequent among critically ill patients with COVID-19. Limited data are available in non-intensive care unit (ICU) patients. Purpose To determine the incidence, risk factors and prognosis of venous thromboembolism (VTE) in non-ICU COVID-19 patients. Methods We studied consecutive COVID-19 patients admitted to general ward at Strasbourg Hospital, France (25.02.2020–19.04.2020). The primary outcome was any VTE complication. The secondary outcome was the composite of death or transfer to ICU. Results Among the 289 patients included (62.2 ± 17.0 years, 59.2% male), VTE occurred in 49 (17.0%). Padua prediction score for VTE was similar between VTE and non-VTE patients. VTE imaging tests were performed in 100 (34.6%) patients and VTE diagnosed in median 7 (3–11) days after admission. On-admission, time from symptom onset to admission (OR 1.07, CI 95% [1.00–1.16], P = 0.045), Improve score (OR 1.37, [1.02–1.83], P = 0.032), leukocyte count (OR 1.16, [1.06–1.27], P = 0.001) and lack of thromboprophylaxis (OR 27.85, CI 95% [9.35–82.95], P < 0.001) were independent predictors of VTE. The incidence of the composite of death or ICU transfer was 31.0% and more frequent among patients with VTE (47.9% vs. 27.9%, P = 0.01). Fever (OR 5.37, CI 95% [1.44–19.97], P = 0.012), VTE (OR 3.44, CI 95% [1.63–7.25], P = 0.001), lymphopenia (OR 0.32, 95% CI [0.15–0.71]; P = 0.005) and extent of COVID-19 evaluated by chest CT severity (OR 1.56, 95% CI [1.12–2.16]; P = 0.007) were independently associated with in-hospital death or transfer to ICU (Table 1, Fig. 1). Conclusions The 17.0% incidence of VTE in non-ICU patients with COVID-19 was associated with worse outcomes. Given the high incidence of VTE in ward patients, there is an urgent need to investigate the optimal anticoagulation regimen.
Collapse
|
31
|
Matsushita K, Hagihara K, Motoki Y, Sakisaka H, Akiyama Y, Nakaguchi K, Doi S. [Locally Advanced Breast Cancer Successfully Treated with Abemaciclib and Fulvestrant-A Case Report]. Gan To Kagaku Ryoho 2020; 47:2165-2167. [PMID: 33468895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
A 78-year-old woman visited our hospital for a tumor in her left breast with discharge. The 10 cm tumor had ulceration and foul smell. Scirrhous breast carcinoma was diagnosed based on core-needle biopsy findings. Chest and abdominal computed tomography( CT) revealed the tumor invading the pectoralis major muscle and a large number of swollen lymph nodes from the left axilla to the subclavian region, but no distant metastases. After 6 months of locally advanced breast cancer treatment with abemaciclib and fulvestrant, ulceration improved. CT revealed that the tumor and lymph nodes tended to shrink. Left mastectomy with axillary lymph node dissection and combined resection of pectoralis major muscle was performed. Postoperative pathological histology revealed ypT2, ypN0, ypM0, ypStage ⅡA. Subsequently, abemaciclib plus fulvestrant therapy was continued as an adjuvant therapy. The patient has survived without recurrence 6 months after the operation. We report a case of locally advanced breast cancer in which abemaciclib and fulvestrant were effective.
Collapse
|
32
|
Matsushita K, Marchandot B, Kibler M, Sato C, Heger J, Peillex M, Trimaille A, Hess S, Grunebaum L, Ohana M, Reydel A, Jesel L, Ohlmann P, Morel O. P2Y12 inhibition by clopidogrel increases adverse clinical outcomes in patients undergoing transcatheter aortic valve replacement. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Current recommendations support short-term dual antiplatelet therapy (DAPT) for patients undergoing transcatheter aortic valve replacement (TAVR) despite no relevant study exploring the extent of platelet inhibition by clopidogrel.
Purpose
To assess whether P2Y12 inhibition by clopidogrel as evaluated by vasodilator-stimulated phosphoprotein flow cytometry test (VASP-FCT) impacts 1-year clinical outcomes in patients undergoing TAVR.
Methods
Patients were included in a prospective registry between February 2010 and May 2019. VASP-FCT was assessed 24h after the procedure. Responder to clopidogrel was defined by a platelet reactivity index ≤50%.
Results
Of 640 patients who underwent TAVR with preprocedural clopidogrel therapy, we enrolled 491 patients for whom VASP data were available. Responders were identified in 22% (n=110) of patients and low responders were 78% (n=381) of patients. Low body mass index, active cancer, and clopidogrel on admission were found to be independent predictors of responder. Mean transaortic pressure gradient was lower in the responder group at 1-month post-TAVR (9.9±4.4 mmHg vs. 11.2±5.8 mmHg, p=0.03) but was similar at 1-year (11.5±6.2 mmHg vs. 11.9±7.4 mmHg, p=0.74). By multivariate Cox regression analysis, patients responding to clopidogrel (hazard ratio [HR]: 2.19; 95% confidence interval [CI]: 1.04 to 3.64; p=0.04), prior PCI (HR: 2.12; 95% CI: 1.07 to 4.37; p=0.03), and mean transaortic pressure gradient at baseline (HR: 0.07; 95% CI: 0.01 to 0.70; p=0.02) were identified as independent predictors of 1-year adverse clinical outcomes, including all-cause death, myocardial infarction, stroke, and heart failure hospitalization.
Conclusions
Appropriate P2Y12 inhibition by clopidogrel is a major determinant of adverse clinical events after TAVR. In sum, the present data challenges the need of DAPT as a standard therapy during TAVR.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Matsushita
- University Hospital of Strasbourg, Strasbourg, France
| | - B Marchandot
- University Hospital of Strasbourg, Strasbourg, France
| | - M Kibler
- University Hospital of Strasbourg, Strasbourg, France
| | - C Sato
- University Hospital of Strasbourg, Strasbourg, France
| | - J Heger
- University Hospital of Strasbourg, Strasbourg, France
| | - M Peillex
- University Hospital of Strasbourg, Strasbourg, France
| | - A Trimaille
- University Hospital of Strasbourg, Strasbourg, France
| | - S Hess
- University Hospital of Strasbourg, Strasbourg, France
| | - L Grunebaum
- University Hospital of Strasbourg, Strasbourg, France
| | - M Ohana
- University Hospital of Strasbourg, Strasbourg, France
| | - A Reydel
- University Hospital of Strasbourg, Strasbourg, France
| | - L Jesel
- University Hospital of Strasbourg, Strasbourg, France
| | - P Ohlmann
- University Hospital of Strasbourg, Strasbourg, France
| | - O Morel
- University Hospital of Strasbourg, Strasbourg, France
| |
Collapse
|
33
|
Lachmet-Thebaud L, Marchandot B, Matsushita K, Sato C, Dagrenat C, Greciano S, De Poli F, Leddet P, Peillex M, Hess S, Carmona A, Reydel A, Ohlmann P, Jesel L, Morel O. Residual inflammation is a major determinant of myocardial recovery and cardiovascular outcome in takotsubo patients. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1835] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Recent insights have emphasized the importance of myocardial and systemic inflammation in Takotsubo Syndrome (TTS).
Objective
In a large registry of unselected patients, we sought to evaluate whether residual high inflammatory response (RHIR) could impact cardiovascular outcome after TTS.
Methods
Patients with TTS were retrospectively included between 2008 and 2018 in three general hospitals. 385 patients with TTS were split into three subgroups, according to tertiles of C-reactive protein (CRP) levels at discharge (CRP<5.2 mg/l, CRP range 5.2 to 19 mg/l, and CRP>19 mg/L). The primary endpoint was the impact of RHIR, defined as CRP>19 mg/L at discharge, on cardiac death or hospitalization for heart failure.
Results
Follow-up was obtained in 382 patients (99%) after a median of 747 days. RHIR patients were more likely to have a history of cancer or a physical trigger. Left ventricular ejection fraction (LVEF) at admission and at discharge were comparable between groups. By contrast, RHIR was associated with lower LVEF at follow-up (61.7 vs. 60.7 vs. 57.9%; p=0.004) and increased cardiac late mortality (0% vs. 0% vs. 10%; p=0.001). By multivariate Cox regression analysis, RHIR was an independent predictor of cardiac death or hospitalization for heart failure (hazard ratio: 1.97; 95% confidence interval: 1.11 to 3.49; p=0.02).
Conclusions
RHIR was associated with impaired LVEF recovery and was evidenced as an independent factor of cardiovascular events. All together these findings underline RHIR patients as a high-risk subgroup, to target in future clinical trials with specific therapies to attenuate RHIR.
Main results
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): GERCA (Groupe pour l'Enseignement, la prévention et la Recherche Cardiovasculaire en Alsace)
Collapse
Affiliation(s)
| | - B Marchandot
- Civil Hospital/Nouvel Hopital Civil, Strasbourg, France
| | - K Matsushita
- Civil Hospital/Nouvel Hopital Civil, Strasbourg, France
| | - C Sato
- Civil Hospital/Nouvel Hopital Civil, Strasbourg, France
| | - C Dagrenat
- Haguenau Hospital Centre, Cardiology, Haguenau, France
| | - S Greciano
- Civil Hospital of Colmar, Colmar, France
| | - F De Poli
- Haguenau Hospital Centre, Cardiology, Haguenau, France
| | - P Leddet
- Civil Hospital of Colmar, Colmar, France
| | - M Peillex
- Civil Hospital/Nouvel Hopital Civil, Strasbourg, France
| | - S Hess
- Civil Hospital/Nouvel Hopital Civil, Strasbourg, France
| | - A Carmona
- Civil Hospital/Nouvel Hopital Civil, Strasbourg, France
| | - A Reydel
- Civil Hospital/Nouvel Hopital Civil, Strasbourg, France
| | - P Ohlmann
- Civil Hospital/Nouvel Hopital Civil, Strasbourg, France
| | - L Jesel
- Civil Hospital/Nouvel Hopital Civil, Strasbourg, France
| | - O Morel
- Civil Hospital/Nouvel Hopital Civil, Strasbourg, France
| |
Collapse
|
34
|
Bruckert C, Remila L, Matsushita K, Auger C, Houngue U, Chaker A, Park S, Algara-Suarez P, Belcastro E, Jesel L, Ohlmann P, Morel O, Schini-Kerth V. Empagliflozin treatment does not affect the hypertensive response to Ang II administration to rats but decreases oxidative stress in the arterial wall, and endothelial and cardiac dysfunction. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Selective sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown cardiovascular protection in type 2 diabetes patients with established cardiovascular disease independently of glycemic control. Angiotensin II (Ang II) and H2O2 have been shown to be strong inducers of the expression of SGLT2 and 1 in endothelial cells promoting oxidative stress and endothelial dysfunction.
Purpose
This study examined the cardiovascular protective effect of empagliflozin (empa) in a normoglycemic experimental model of hypertension in the rat.
Methods
Male Wistar rats received empa (30 mg/kg/day) provided in the diet for 5 weeks. After 1 week, rats underwent sham surgery (sham rats) or surgery with implantation of an osmotic mini-pump infusing Ang II (0.4 mg/kg/d) for 4 weeks. Systolic blood pressure (SBP) was assessed by sphygmomanometry, the cardiac function using echocardiography, the expression level of target proteins by immunofluorescence staining, and the level of oxidative stress using dihydroethidium staining.
Results
Angiotensin II administration increased systolic blood pressure from about 130 to 180 mmHg, which was not affected by the empa treatment. The 4-week Ang II treatment did not significantly affect the systolic cardiac function (cardiac output, left ventricle ejection fraction) but impaired the diastolic function as indicated by a reduced E' and IVRT values, and an increased E/E' value. The Ang II treatment increased significantly the heart and right ventricle weight whereas the left ventricle + septum weight was slightly but not significantly increased. No such functional and structural changes were observed in the Ang II + empa treatment group. An increased immunofluorescence eNOS signal in the endothelium, and a higher level of ROS throughout the aorta wall were observed in the Ang II-treated group, both of which were significantly reduced in the empa + Ang II-treated group. In the Ang II-treated group, the high level of oxidative stress in the aorta was significantly reduced by the AT1 receptor antagonist losartan, the NADPH oxidase inhibitor VAS-2871, the eNOS inhibitor NG-nitro-L-arginine and also to a greater extent by the selective SGLT2 inhibitor empa compared to the dual SGLT1/2 inhibitor sotagliflozin.
Conclusion(s)
The present findings indicate that although the empa treatment did not affect the hypertensive response of rats to Ang II, the SGLT2 inhibitor prevented the deleterious impact of Ang II on the diastolic cardiac function and remodeling, and the upregulation of eNOS expression and oxidative stress in the aorta wall. Thus, these findings highlight the protective potential of empa on the cardiovascular system in a normoglycemic hypertensive experimental model.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Boehringer Ingelheim Pharma GmbH & Co KG (Biberach an der Riss, Germany)
Collapse
Affiliation(s)
- C Bruckert
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - L Remila
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - K Matsushita
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - C Auger
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - U Houngue
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - A Chaker
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - S Park
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - P Algara-Suarez
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - E Belcastro
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - L Jesel
- University Hospital Strasbourg, Cardiology, Strasbourg, France
| | - P Ohlmann
- University Hospital Strasbourg, Cardiology, Strasbourg, France
| | - O Morel
- University Hospital Strasbourg, Cardiology, Strasbourg, France
| | - V Schini-Kerth
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| |
Collapse
|
35
|
Takei M, Harada K, Miyazaki T, Kohsaka S, Matsushita K, Shiraishi Y, Shinme T, Shindo A, Miyamoto T, Kitano D, Kodera S, Nakano H, Yamamoto T, Takayama M. Effect of air pollution on acute heart failure hospitalization differ across specific heart failure populations. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Several report showed the association between ambient air pollution including particular matter under 2.5um (PM2.5) and increasing rate of hospitalization for heart failure. However, these report analyzed mainly cross-sectional, epidemiological data, thus the reports regarding association between vulnerability to PM2.5 and specific populations in acute heart failure (AHF) were scarce.
Purpose
1. To analyze the association between air pollution and rate of hospitalization for AHF
2. To analyze whether the vulnerability to air pollution differ between specific populations in AHF. Methods
A case-cross over analysis was conducted to 4980 consecutive patients registered for multicenter acute heart failure registry in 2017 in our city Japan. This registry enrolled patients transferred to cardiovascular care unit (80 institutions) via emergency medical services across our city area. Logistic regression analysis were conducted to estimate percentage changes in the rate of acute heart failure hospitalization associated with per 1μg/m3 PM2.5 concentration increase. We also conducted subgroup analysis for patients stratified by age, gender, comorbidities, left ventricular ejection fraction, and clinical scenario.
Results
An increase in 1 μg/m3 PM2.5 concentration corresponded to 2.9% (95% CI 1.2–4.6%) increase in AHF hospitalization. Patients with age younger than 75, without prior heart failure hospitalization, without history of hypertension, without anemia, and with reduced ejection fraction were more susceptible to increase in PM2.5 concentration (Figure).
Conclusions
Increase in PM2.5 concentration was associated with increased rate of AHF hospitalization. Effect of PM2.5 may differ across specific AHF subpopulations.
Figure 1
Funding Acknowledgement
Type of funding source: Other. Main funding source(s): Tokyo Metropolitan Government
Collapse
Affiliation(s)
- M Takei
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - K Harada
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - T Miyazaki
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - S Kohsaka
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - K Matsushita
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - Y Shiraishi
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - T Shinme
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - A Shindo
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - T Miyamoto
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - D Kitano
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - S Kodera
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - H Nakano
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - T Yamamoto
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - M Takayama
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| |
Collapse
|
36
|
Matsushita K, Marchandot B, Kibler M, Sato C, Heger J, Peillex M, Trimaille A, Hess S, Grunebaum L, Ohana M, Reydel A, Jesel L, Ohlmann P, Morel O. Predictive impact of PVL assessments on clinical outcomes in patients undergoing TAVR. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Paravalvular leakage (PVL) following transcatheter aortic valve replacement (TAVR) is associated with greater mortality. In clinical practice, determining PVL severity after TAVR remains challenging and often requires multiparametric assessment.
Purpose
This study sought to evaluate the respective value of various modalities of PVL assessments, including transthoracic echocardiography (TTE), cine-angiography, aortic regurgitation index (ARI), and closure time with adenosine diphosphate (CT-ADP), in the prediction of adverse clinical outcomes.
Methods
We included 1044 patients from our prospective TAVR registry between February 2010 and May 2019. Major adverse cardiac and cerebrovascular events (MACCE) was defined as a composite of all-cause death, myocardial infarction, stroke, and heart failure hospitalization within 1-year. Established cutoff values of ARI (<25) and CT-ADP (>180 sec) were used to assess the presence of PVL after TAVR.
Results
Moderate to severe PVL occurred in 14.2% and 5.2% of patients as measured by TTE and angiography. The rate of patients with ARI <25 and CT-ADP >180 sec were 36.5% and 24.9%, respectively. Among the four modalities, PVL evaluated by angiography predicted poorer clinical outcomes (Log rank test; p=0.001), whereas TTE, ARI <25, and CT-ADP >180 sec were not associated with 1-year MACCE. By multivariate Cox regression analysis, moderate to severe PVL by angiography was an independent predictor of 1-year MACCE (hazard ratio: 1.96; 95% confidence interval: 1.22–3.00; p=0.007).
Conclusions
Paravalvular leakage measured by angiography was evidenced as the most meaningful modality in the prediction of adverse clinical outcomes. Future multicenter studies are warranted to ensure these findings in the current TAVR era.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Matsushita
- University Hospital of Strasbourg, Strasbourg, France
| | - B Marchandot
- University Hospital of Strasbourg, Strasbourg, France
| | - M Kibler
- University Hospital of Strasbourg, Strasbourg, France
| | - C Sato
- University Hospital of Strasbourg, Strasbourg, France
| | - J Heger
- University Hospital of Strasbourg, Strasbourg, France
| | - M Peillex
- University Hospital of Strasbourg, Strasbourg, France
| | - A Trimaille
- University Hospital of Strasbourg, Strasbourg, France
| | - S Hess
- University Hospital of Strasbourg, Strasbourg, France
| | - L Grunebaum
- University Hospital of Strasbourg, Strasbourg, France
| | - M Ohana
- University Hospital of Strasbourg, Strasbourg, France
| | - A Reydel
- University Hospital of Strasbourg, Strasbourg, France
| | - L Jesel
- University Hospital of Strasbourg, Strasbourg, France
| | - P Ohlmann
- University Hospital of Strasbourg, Strasbourg, France
| | - O Morel
- University Hospital of Strasbourg, Strasbourg, France
| |
Collapse
|
37
|
Matsushita K, Lachmet-Thebaud L, Marchandot B, Sato C, Dagrenat C, Greciano S, De Poli F, Leddet P, Trimaille A, Heger J, Reydel A, Trinh A, Ohlmann P, Jesel L, Morel O. Incomplete recovery of takotsubo cardiomyopathy is a major determinant of cardiovascular mortality. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Although there is an apparent rapid and spontaneous recovery of left ventricular ejection fraction (LVEF) in patients with takotsubo cardiomyopathy, recent studies have demonstrated the long-lasting functional impairment in those patients.
Purpose
We sought to evaluate the predictors of incomplete recovery in chronic phase and its impact on cardiovascular mortality after takotsubo cardiomyopathy.
Methods
Patients with takotsubo cardiomyopathy between 2008 and 2018 were retrospectively enrolled in three different institutions. Takotsubo cardiomyopathy was diagnosed according to the European Society of Cardiology Heart Failure Association criteria. After exclusion of in-hospital deaths, 407 patients were split into 2 subgroups according whether their LVEF were >50% (recovery group; n=333), or ≤50% (incomplete recovery group; n=74) at follow-up. The primary endpoint was the impact of incomplete recovery on cardiovascular mortality.
Results
Patients with incomplete recovery were more likely to be male, to have dementia, pacemaker, and supraventricular arrhythmia. C-reactive protein (CRP) levels on admission, at peak, and at discharge were significantly higher in patients with incomplete recovery. By multivariate logistic regression analysis, lower EF at discharge (odds ratio [OR]: 0.91; 95% confidence interval [CI]: 0.88 to 0.95; p<0.001) and higher CRP levels (OR: 5.56; 95% CI: 1.86 to 16.61; p<0.001) were independent predictors of incomplete recovery at follow-up. The cumulative event-free survival rate according to cardiovascular death was significantly lower in the incomplete recovery group (p<0.001; log-rank test).
Conclusions
We demonstrate that incomplete recovery after takotsubo cardiomyopathy is characterized by a residual systemic inflammation and an increased cardiac mortality at follow-up. Altogether, our findings underline patients with persistent inflammation as a high-risk subgroup, to target in future clinical trials with specific therapies to attenuate inflammation.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Matsushita
- University Hospital of Strasbourg, Strasbourg, France
| | | | - B Marchandot
- University Hospital of Strasbourg, Strasbourg, France
| | - C Sato
- University Hospital of Strasbourg, Strasbourg, France
| | - C Dagrenat
- Haguenau Hospital Centre, Haguenau, France
| | - S Greciano
- Civil Hospital of Colmar, Colmar, France
| | - F De Poli
- Haguenau Hospital Centre, Haguenau, France
| | - P Leddet
- Haguenau Hospital Centre, Haguenau, France
| | - A Trimaille
- University Hospital of Strasbourg, Strasbourg, France
| | - J Heger
- University Hospital of Strasbourg, Strasbourg, France
| | - A Reydel
- University Hospital of Strasbourg, Strasbourg, France
| | - A Trinh
- University Hospital of Strasbourg, Strasbourg, France
| | - P Ohlmann
- University Hospital of Strasbourg, Strasbourg, France
| | - L Jesel
- University Hospital of Strasbourg, Strasbourg, France
| | - O Morel
- University Hospital of Strasbourg, Strasbourg, France
| |
Collapse
|
38
|
Eguchi H, Iwagami Y, Matsushita K, Tomimaru Y, Akita H, Noda T, Gotoh K, Kobayashi S, Nagano H, Mori M, Doki Y. Randomized clinical trial of pancreaticogastrostomy versus pancreaticojejunostomy regarding incidence of delayed gastric emptying after pancreaticoduodenectomy. Langenbecks Arch Surg 2020; 405:921-928. [PMID: 32901299 DOI: 10.1007/s00423-020-01982-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2020] [Accepted: 09/01/2020] [Indexed: 02/08/2023]
Abstract
PURPOSE Delayed gastric emptying (DGE) is an important postoperative complication after pancreaticoduodenectomy (PD), and its incidence may be associated with the utilized surgical procedures. Compared with pancreaticojejunostomy (PJ) after PD, it may be speculated that pancreaticogastrostomy (PG) is a risk factor for DGE, because it needs an anastomosis of the remnant pancreas to the back wall of the stomach. This study aimed to compare PG and PJ with regard to the incidence of DGE after PD. METHODS We performed a prospective open-label randomized clinical trial (RCT) including patients undergoing elective pancreaticoduodenectomy, who were randomly assigned PG or PJ the day before surgery. The primary endpoint was incidence of DGE. RESULTS The study included 60 patients (30 PG, 30 PJ), of whom seven were deemed unresectable, one was enucleated, and one was switched from PJ to PG during surgery according to the surgeon's decision. Thus, modified intention-to-treat analyses were performed in 27 PG patients and 26 PJ patients. DGE occurred in three patients in the PG group and six patients in the PJ group, which did not constitute a significant between-group difference (P = 0.42). In the PG group, two cases were ISGPS grade A DGE and one was grade C. In the PJ group, one case was grade A, two grade B, and three grade C. The two groups also did not significantly differ in the incidence of other morbidities or postoperative hospital stay. CONCLUSIONS Post-PD DGE incidences were similar after PG and PJ.
Collapse
Affiliation(s)
- Hidetoshi Eguchi
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. .,Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group, Osaka, Japan.
| | - Yoshifumi Iwagami
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.,Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group, Osaka, Japan
| | - Katsunori Matsushita
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.,Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group, Osaka, Japan
| | - Yoshito Tomimaru
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.,Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group, Osaka, Japan
| | - Hirofumi Akita
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.,Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group, Osaka, Japan
| | - Takehiro Noda
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.,Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group, Osaka, Japan
| | - Kunihito Gotoh
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.,Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group, Osaka, Japan
| | - Shogo Kobayashi
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.,Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group, Osaka, Japan
| | - Hiroaki Nagano
- Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group, Osaka, Japan.,Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan
| | - Masaki Mori
- Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group, Osaka, Japan.,Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, Fukuoka, 812-8582, Japan
| | - Yuichiro Doki
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.,Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group, Osaka, Japan
| |
Collapse
|
39
|
Ooi K, Inoue N, Matsushita K, Mikoya T, Minowa K, Kawashiri S, Tei K. Relations between anterior disc displacement and maxillomandibular morphology in skeletal anterior open bite with changes to the mandibular condyle. Br J Oral Maxillofac Surg 2020; 58:1084-1090. [PMID: 32654798 DOI: 10.1016/j.bjoms.2020.05.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2019] [Accepted: 05/15/2020] [Indexed: 10/23/2022]
Abstract
In this study we investigated the relation between anterior disc displacement (ADD) and maxillomandibular morphology in skeletal anterior open bite with changes to the mandibular condyle. Thirty female patients (60 joints) with both conditions were evaluated. Magnetic resonance imaging of the temporomandibular joint (TMJ) was used to diagnose both ADD and changes to the mandibular condyle (erosion, osteophyte, and deformity). The relations among ADD, changes to the mandibular condyle, and maxillomandibular morphology were examined statistically. Changes to the mandibular condyle had a higher score than sym anterior open bite, the deviated side in asymmetric anterior open bite, and the non-deviated side. The score for disc displacement on the non-deviated side was lower than both the sym side and the deviated side. Unilateral changes to the mandibular condyle and unilateral disc displacement were not apparent in sym anterior open bite, but a unilateral non-displaced disc was seen only on the asymmetric side. Mandibular condylar changes were significantly more common on the deviated, than on the non-deviated, side. The SNB angle was significantly smaller, and the ANB, GZN, and SN-mandibular plane angles were significantly larger in sym anterior open bite. Overjet, ANB angle, GZN angle, and SN-MP angle were significantly larger, and the SNB angle was significantly smaller, in the presence of ADD without reduction and mandibular condylar deformity. We conclude that the prevalence of ADD without reduction and changes to the mandibular condyle were related to mandibular asymmetry and mandibular morphology in anterior open bite. This retrospective study suggests that ADD without reduction and mandibular condylar bone changes may be related to the progression of skeletal class II open bite and mandibular asymmetry in cases of skeletal open bite.
Collapse
Affiliation(s)
- K Ooi
- Oral and Maxillofacial Surgery, Department of Oral Patho-biological Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 kita-ku, Sapporo, Hokkaido 060-8586, Japan; Department of Oral and Maxillofacial Surgery, Graduate School of Medical Science, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
| | - N Inoue
- Gerodontology, Department of Oral Health Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 Kita-ku, Sapporo, Hokkaido 060-8586, Japan
| | - K Matsushita
- Oral and Maxillofacial Surgery, Department of Oral Patho-biological Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 kita-ku, Sapporo, Hokkaido 060-8586, Japan
| | - T Mikoya
- Oral and Maxillofacial Surgery, Department of Oral Patho-biological Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 kita-ku, Sapporo, Hokkaido 060-8586, Japan
| | - K Minowa
- Dental Radiology, Department of Oral Health Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 kita-ku, Sapporo, Hokkaido 060-8586, Japan
| | - S Kawashiri
- Department of Oral and Maxillofacial Surgery, Graduate School of Medical Science, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan
| | - K Tei
- Oral and Maxillofacial Surgery, Department of Oral Patho-biological Science, Graduate School of Dental Medicine, Hokkaido University, Kita 13 Nishi 7 kita-ku, Sapporo, Hokkaido 060-8586, Japan
| |
Collapse
|
40
|
Abe K, Akutsu R, Ali A, Alt C, Andreopoulos C, Anthony L, Antonova M, Aoki S, Ariga A, Asada Y, Ashida Y, Atkin ET, Awataguchi Y, Ban S, Barbi M, Barker GJ, Barr G, Barrow D, Barry C, Batkiewicz-Kwasniak M, Beloshapkin A, Bench F, Berardi V, Berkman S, Berns L, Bhadra S, Bienstock S, Blondel A, Bolognesi S, Bourguille B, Boyd SB, Brailsford D, Bravar A, Bravo Berguño D, Bronner C, Bubak A, Buizza Avanzini M, Calcutt J, Campbell T, Cao S, Cartwright SL, Catanesi MG, Cervera A, Chappell A, Checchia C, Cherdack D, Chikuma N, Christodoulou G, Coleman J, Collazuol G, Cook L, Coplowe D, Cudd A, Dabrowska A, De Rosa G, Dealtry T, Denner PF, Dennis SR, Densham C, Di Lodovico F, Dokania N, Dolan S, Doyle TA, Drapier O, Dumarchez J, Dunne P, Eklund L, Emery-Schrenk S, Ereditato A, Fernandez P, Feusels T, Finch AJ, Fiorentini GA, Fiorillo G, Francois C, Friend M, Fujii Y, Fujita R, Fukuda D, Fukuda R, Fukuda Y, Fusshoeller K, Gameil K, Giganti C, Golan T, Gonin M, Gorin A, Guigue M, Hadley DR, Haigh JT, Hamacher-Baumann P, Hartz M, Hasegawa T, Hastings NC, Hayashino T, Hayato Y, Hiramoto A, Hogan M, Holeczek J, Hong Van NT, Iacob F, Ichikawa AK, Ikeda M, Ishida T, Ishii T, Ishitsuka M, Iwamoto K, Izmaylov A, Jakkapu M, Jamieson B, Jenkins SJ, Jesús-Valls C, Jiang M, Johnson S, Jonsson P, Jung CK, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Karlen D, Kasetti SP, Kataoka Y, Katori T, Kato Y, Kearns E, Khabibullin M, Khotjantsev A, Kikawa T, Kim H, Kim J, King S, Kisiel J, Knight A, Knox A, Kobayashi T, Koch L, Koga T, Konaka A, Kormos LL, Koshio Y, Kostin A, Kowalik K, Kubo H, Kudenko Y, Kukita N, Kuribayashi S, Kurjata R, Kutter T, Kuze M, Labarga L, Lagoda J, Lamoureux M, Laveder M, Lawe M, Licciardi M, Lindner T, Litchfield RP, Liu SL, Li X, Longhin A, Ludovici L, Lu X, Lux T, Machado LN, Magaletti L, Mahn K, Malek M, Manly S, Maret L, Marino AD, Marti-Magro L, Martin JF, Maruyama T, Matsubara T, Matsushita K, Matveev V, Mavrokoridis K, Mazzucato E, McCarthy M, McCauley N, McFarland KS, McGrew C, Mefodiev A, Metelko C, Mezzetto M, Minamino A, Mineev O, Mine S, Miura M, Molina Bueno L, Moriyama S, Morrison J, Mueller TA, Munteanu L, Murphy S, Nagai Y, Nakadaira T, Nakahata M, Nakajima Y, Nakamura A, Nakamura KG, Nakamura K, Nakayama S, Nakaya T, Nakayoshi K, Nantais C, Ngoc TV, Niewczas K, Nishikawa K, Nishimura Y, Nonnenmacher TS, Nova F, Novella P, Nowak J, Nugent JC, O'Keeffe HM, O'Sullivan L, Odagawa T, Okumura K, Okusawa T, Oser SM, Owen RA, Oyama Y, Palladino V, Palomino JL, Paolone V, Parker WC, Pasternak J, Paudyal P, Pavin M, Payne D, Penn GC, Pickering L, Pidcott C, Pintaudi G, Pinzon Guerra ES, Pistillo C, Popov B, Porwit K, Posiadala-Zezula M, Pritchard A, Quilain B, Radermacher T, Radicioni E, Radics B, Ratoff PN, Reinherz-Aronis E, Riccio C, Rondio E, Roth S, Rubbia A, Ruggeri AC, Ruggles CA, Rychter A, Sakashita K, Sánchez F, Schloesser CM, Scholberg K, Schwehr J, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shah R, Shaikhiev A, Shaker F, Shaykina A, Shiozawa M, Shorrock W, Shvartsman A, Smirnov A, Smy M, Sobczyk JT, Sobel H, Soler FJP, Sonoda Y, Steinmann J, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Sztuc AA, Tada M, Tajima M, Takeda A, Takeuchi Y, Tanaka HK, Tanaka HA, Tanaka S, Thompson LF, Toki W, Touramanis C, Towstego T, Tsui KM, Tsukamoto T, Tzanov M, Uchida Y, Uno W, Vagins M, Valder S, Vallari Z, Vargas D, Vasseur G, Vilela C, Vinning WGS, Vladisavljevic T, Volkov VV, Wachala T, Walker J, Walsh JG, Wang Y, Wark D, Wascko MO, Weber A, Wendell R, Wilking MJ, Wilkinson C, Wilson JR, Wilson RJ, Wood K, Wret C, Yamada Y, Yamamoto K, Yanagisawa C, Yang G, Yano T, Yasutome K, Yen S, Yershov N, Yokoyama M, Yoshida T, Yu M, Zalewska A, Zalipska J, Zaremba K, Zarnecki G, Ziembicki M, Zimmerman ED, Zito M, Zsoldos S, Zykova A. Search for Electron Antineutrino Appearance in a Long-Baseline Muon Antineutrino Beam. Phys Rev Lett 2020; 124:161802. [PMID: 32383902 DOI: 10.1103/physrevlett.124.161802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 02/26/2020] [Accepted: 03/25/2020] [Indexed: 06/11/2023]
Abstract
Electron antineutrino appearance is measured by the T2K experiment in an accelerator-produced antineutrino beam, using additional neutrino beam operation to constrain parameters of the Pontecorvo-Maki-Nakagawa-Sakata (PMNS) mixing matrix. T2K observes 15 candidate electron antineutrino events with a background expectation of 9.3 events. Including information from the kinematic distribution of observed events, the hypothesis of no electron antineutrino appearance is disfavored with a significance of 2.40σ and no discrepancy between data and PMNS predictions is found. A complementary analysis that introduces an additional free parameter which allows non-PMNS values of electron neutrino and antineutrino appearance also finds no discrepancy between data and PMNS predictions.
Collapse
Affiliation(s)
- K Abe
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - R Akutsu
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - A Ali
- Kyoto University, Department of Physics, Kyoto, Japan
| | - C Alt
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - C Andreopoulos
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - L Anthony
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Antonova
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - S Aoki
- Kobe University, Kobe, Japan
| | - A Ariga
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - Y Asada
- Yokohama National University, Faculty of Engineering, Yokohama, Japan
| | - Y Ashida
- Kyoto University, Department of Physics, Kyoto, Japan
| | - E T Atkin
- Imperial College London, Department of Physics, London, United Kingdom
| | - Y Awataguchi
- Tokyo Metropolitan University, Department of Physics, Tokyo, Japan
| | - S Ban
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Barbi
- University of Regina, Department of Physics, Regina, Saskatchewan, Canada
| | - G J Barker
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - G Barr
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - D Barrow
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - C Barry
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | | | - A Beloshapkin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F Bench
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - V Berardi
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - S Berkman
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - L Berns
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - S Bhadra
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - S Bienstock
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - A Blondel
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | | | - B Bourguille
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - S B Boyd
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - D Brailsford
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - A Bravar
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - D Bravo Berguño
- University Autonoma Madrid, Department of Theoretical Physics, Madrid, Spain
| | - C Bronner
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - A Bubak
- University of Silesia, Institute of Physics, Katowice, Poland
| | - M Buizza Avanzini
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - J Calcutt
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - T Campbell
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - S Cao
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - S L Cartwright
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - M G Catanesi
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - A Cervera
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - A Chappell
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - C Checchia
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - D Cherdack
- University of Houston, Department of Physics, Houston, Texas, USA
| | - N Chikuma
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - G Christodoulou
- CERN European Organization for Nuclear Research, CH-1211 Genève 23, Switzerland
| | - J Coleman
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - G Collazuol
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - L Cook
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - D Coplowe
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - A Cudd
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - A Dabrowska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - G De Rosa
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - T Dealtry
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - P F Denner
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - S R Dennis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - C Densham
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - F Di Lodovico
- King's College London, Department of Physics, Strand, London WC2R 2LS, United Kingdom
| | - N Dokania
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - S Dolan
- CERN European Organization for Nuclear Research, CH-1211 Genève 23, Switzerland
| | - T A Doyle
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - O Drapier
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - J Dumarchez
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - P Dunne
- Imperial College London, Department of Physics, London, United Kingdom
| | - L Eklund
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | | | - A Ereditato
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - P Fernandez
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - T Feusels
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - A J Finch
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - G A Fiorentini
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - G Fiorillo
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - C Francois
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - M Friend
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Fujii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - R Fujita
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - D Fukuda
- Okayama University, Department of Physics, Okayama, Japan
| | - R Fukuda
- Tokyo University of Science, Faculty of Science and Technology, Department of Physics, Noda, Chiba, Japan
| | - Y Fukuda
- Miyagi University of Education, Department of Physics, Sendai, Japan
| | - K Fusshoeller
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - K Gameil
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - C Giganti
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - T Golan
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - M Gonin
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - A Gorin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Guigue
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - D R Hadley
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - J T Haigh
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | | | - M Hartz
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- TRIUMF, Vancouver, British Columbia, Canada
| | - T Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - N C Hastings
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Hayashino
- Kyoto University, Department of Physics, Kyoto, Japan
| | - Y Hayato
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - A Hiramoto
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Hogan
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - J Holeczek
- University of Silesia, Institute of Physics, Katowice, Poland
| | - N T Hong Van
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
- International Centre of Physics, Institute of Physics (IOP), Vietnam Academy of Science and Technology (VAST), 10 Dao Tan, Ba Dinh, Hanoi, Vietnam
| | - F Iacob
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - A K Ichikawa
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Ikeda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - T Ishida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Ishii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Ishitsuka
- Tokyo University of Science, Faculty of Science and Technology, Department of Physics, Noda, Chiba, Japan
| | - K Iwamoto
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - A Izmaylov
- IFIC (CSIC & University of Valencia), Valencia, Spain
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Jakkapu
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - B Jamieson
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - S J Jenkins
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - C Jesús-Valls
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - M Jiang
- Kyoto University, Department of Physics, Kyoto, Japan
| | - S Johnson
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - P Jonsson
- Imperial College London, Department of Physics, London, United Kingdom
| | - C K Jung
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - M Kabirnezhad
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - A C Kaboth
- Royal Holloway University of London, Department of Physics, Egham, Surrey, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - T Kajita
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - H Kakuno
- Tokyo Metropolitan University, Department of Physics, Tokyo, Japan
| | - J Kameda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - D Karlen
- TRIUMF, Vancouver, British Columbia, Canada
- University of Victoria, Department of Physics and Astronomy, Victoria, British Columbia, Canada
| | - S P Kasetti
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - Y Kataoka
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - T Katori
- King's College London, Department of Physics, Strand, London WC2R 2LS, United Kingdom
| | - Y Kato
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - E Kearns
- Boston University, Department of Physics, Boston, Massachusetts, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - M Khabibullin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Khotjantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T Kikawa
- Kyoto University, Department of Physics, Kyoto, Japan
| | - H Kim
- Osaka City University, Department of Physics, Osaka, Japan
| | - J Kim
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - S King
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - J Kisiel
- University of Silesia, Institute of Physics, Katowice, Poland
| | - A Knight
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - A Knox
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - T Kobayashi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - L Koch
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - T Koga
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - A Konaka
- TRIUMF, Vancouver, British Columbia, Canada
| | - L L Kormos
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - Y Koshio
- Okayama University, Department of Physics, Okayama, Japan
| | - A Kostin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K Kowalik
- National Centre for Nuclear Research, Warsaw, Poland
| | - H Kubo
- Kyoto University, Department of Physics, Kyoto, Japan
| | - Y Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - N Kukita
- Osaka City University, Department of Physics, Osaka, Japan
| | - S Kuribayashi
- Kyoto University, Department of Physics, Kyoto, Japan
| | - R Kurjata
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - T Kutter
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - M Kuze
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - L Labarga
- University Autonoma Madrid, Department of Theoretical Physics, Madrid, Spain
| | - J Lagoda
- National Centre for Nuclear Research, Warsaw, Poland
| | - M Lamoureux
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - M Laveder
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - M Lawe
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - M Licciardi
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - T Lindner
- TRIUMF, Vancouver, British Columbia, Canada
| | - R P Litchfield
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - S L Liu
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - X Li
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - A Longhin
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - L Ludovici
- INFN Sezione di Roma and Università di Roma "La Sapienza", Roma, Italy
| | - X Lu
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - T Lux
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - L N Machado
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - L Magaletti
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - K Mahn
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - M Malek
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - S Manly
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - L Maret
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - A D Marino
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - L Marti-Magro
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J F Martin
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - T Maruyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Matsubara
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Matsushita
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - V Matveev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K Mavrokoridis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | | | - M McCarthy
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - N McCauley
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - K S McFarland
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - C McGrew
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - A Mefodiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C Metelko
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Mezzetto
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - A Minamino
- Yokohama National University, Faculty of Engineering, Yokohama, Japan
| | - O Mineev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S Mine
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
| | - M Miura
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - L Molina Bueno
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - S Moriyama
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J Morrison
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - Th A Mueller
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - L Munteanu
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - S Murphy
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - Y Nagai
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - T Nakadaira
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Nakahata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - Y Nakajima
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - A Nakamura
- Okayama University, Department of Physics, Okayama, Japan
| | - K G Nakamura
- Kyoto University, Department of Physics, Kyoto, Japan
| | - K Nakamura
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - S Nakayama
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - T Nakaya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Kyoto University, Department of Physics, Kyoto, Japan
| | - K Nakayoshi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - C Nantais
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - T V Ngoc
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
| | - K Niewczas
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - K Nishikawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Nishimura
- Keio University, Department of Physics, Kanagawa, Japan
| | - T S Nonnenmacher
- Imperial College London, Department of Physics, London, United Kingdom
| | - F Nova
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - P Novella
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - J Nowak
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - J C Nugent
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - H M O'Keeffe
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - L O'Sullivan
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - T Odagawa
- Kyoto University, Department of Physics, Kyoto, Japan
| | - K Okumura
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - T Okusawa
- Osaka City University, Department of Physics, Osaka, Japan
| | - S M Oser
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - R A Owen
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - Y Oyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - V Palladino
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - J L Palomino
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - V Paolone
- University of Pittsburgh, Department of Physics and Astronomy, Pittsburgh, Pennsylvania, USA
| | - W C Parker
- Royal Holloway University of London, Department of Physics, Egham, Surrey, United Kingdom
| | - J Pasternak
- Imperial College London, Department of Physics, London, United Kingdom
| | - P Paudyal
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Pavin
- TRIUMF, Vancouver, British Columbia, Canada
| | - D Payne
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - G C Penn
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - L Pickering
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - C Pidcott
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - G Pintaudi
- Yokohama National University, Faculty of Engineering, Yokohama, Japan
| | - E S Pinzon Guerra
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - C Pistillo
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - B Popov
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - K Porwit
- University of Silesia, Institute of Physics, Katowice, Poland
| | | | - A Pritchard
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - B Quilain
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - T Radermacher
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - E Radicioni
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - B Radics
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - P N Ratoff
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - E Reinherz-Aronis
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - C Riccio
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - E Rondio
- National Centre for Nuclear Research, Warsaw, Poland
| | - S Roth
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - A Rubbia
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - A C Ruggeri
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - C A Ruggles
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - A Rychter
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - K Sakashita
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - F Sánchez
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - C M Schloesser
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - K Scholberg
- Duke University, Department of Physics, Durham, North Carolina, USA
| | - J Schwehr
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - M Scott
- Imperial College London, Department of Physics, London, United Kingdom
| | - Y Seiya
- Osaka City University, Department of Physics, Osaka, Japan
| | - T Sekiguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - H Sekiya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - D Sgalaberna
- CERN European Organization for Nuclear Research, CH-1211 Genève 23, Switzerland
| | - R Shah
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - A Shaikhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F Shaker
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - A Shaykina
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Shiozawa
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - W Shorrock
- Imperial College London, Department of Physics, London, United Kingdom
| | - A Shvartsman
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Smirnov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Smy
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
| | - J T Sobczyk
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - H Sobel
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - F J P Soler
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - Y Sonoda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J Steinmann
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - S Suvorov
- IRFU, CEA Saclay, Gif-sur-Yvette, France
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | | | - S Y Suzuki
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Suzuki
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - A A Sztuc
- Imperial College London, Department of Physics, London, United Kingdom
| | - M Tada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Tajima
- Kyoto University, Department of Physics, Kyoto, Japan
| | - A Takeda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - Y Takeuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Kobe University, Kobe, Japan
| | - H K Tanaka
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - H A Tanaka
- SLAC National Accelerator Laboratory, Stanford University, Menlo Park, California, USA
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - S Tanaka
- Osaka City University, Department of Physics, Osaka, Japan
| | - L F Thompson
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - W Toki
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - C Touramanis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - T Towstego
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - K M Tsui
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - T Tsukamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Tzanov
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - Y Uchida
- Imperial College London, Department of Physics, London, United Kingdom
| | - W Uno
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Vagins
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - S Valder
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - Z Vallari
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - D Vargas
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - G Vasseur
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - C Vilela
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - W G S Vinning
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - T Vladisavljevic
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - V V Volkov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T Wachala
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J Walker
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - J G Walsh
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - Y Wang
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - D Wark
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - M O Wascko
- Imperial College London, Department of Physics, London, United Kingdom
| | - A Weber
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - R Wendell
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M J Wilking
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - C Wilkinson
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - J R Wilson
- King's College London, Department of Physics, Strand, London WC2R 2LS, United Kingdom
| | - R J Wilson
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - K Wood
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - C Wret
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - Y Yamada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Yamamoto
- Osaka City University, Department of Physics, Osaka, Japan
| | - C Yanagisawa
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - G Yang
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - T Yano
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - K Yasutome
- Kyoto University, Department of Physics, Kyoto, Japan
| | - S Yen
- TRIUMF, Vancouver, British Columbia, Canada
| | - N Yershov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Yokoyama
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - T Yoshida
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - M Yu
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - A Zalewska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J Zalipska
- National Centre for Nuclear Research, Warsaw, Poland
| | - K Zaremba
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - G Zarnecki
- National Centre for Nuclear Research, Warsaw, Poland
| | - M Ziembicki
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - E D Zimmerman
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - M Zito
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - S Zsoldos
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - A Zykova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| |
Collapse
|
41
|
Abe K, Akutsu R, Ali A, Alt C, Andreopoulos C, Anthony L, Antonova M, Aoki S, Ariga A, Arihara T, Asada Y, Ashida Y, Atkin ET, Awataguchi Y, Ban S, Barbi M, Barker GJ, Barr G, Barrow D, Barry C, Batkiewicz-Kwasniak M, Beloshapkin A, Bench F, Berardi V, Berkman S, Berns L, Bhadra S, Bienstock S, Blondel A, Bolognesi S, Bourguille B, Boyd SB, Brailsford D, Bravar A, Berguño DB, Bronner C, Bubak A, Avanzini MB, Calcutt J, Campbell T, Cao S, Cartwright SL, Catanesi MG, Cervera A, Chappell A, Checchia C, Cherdack D, Chikuma N, Cicerchia M, Christodoulou G, Coleman J, Collazuol G, Cook L, Coplowe D, Cudd A, Dabrowska A, De Rosa G, Dealtry T, Denner PF, Dennis SR, Densham C, Di Lodovico F, Dokania N, Dolan S, Doyle TA, Drapier O, Dumarchez J, Dunne P, Eguchi A, Eklund L, Emery-Schrenk S, Ereditato A, Fernandez P, Feusels T, Finch AJ, Fiorentini GA, Fiorillo G, Francois C, Friend M, Fujii Y, Fujita R, Fukuda D, Fukuda R, Fukuda Y, Fusshoeller K, Gameil K, Giganti C, Golan T, Gonin M, Gorin A, Guigue M, Hadley DR, Haigh JT, Hamacher-Baumann P, Hartz M, Hasegawa T, Hassani S, Hastings NC, Hayashino T, Hayato Y, Hiramoto A, Hogan M, Holeczek J, Hong Van NT, Iacob F, Ichikawa AK, Ikeda M, Ishida T, Ishii T, Ishitsuka M, Iwamoto K, Izmaylov A, Jakkapu M, Jamieson B, Jenkins SJ, Jesús-Valls C, Jiang M, Johnson S, Jonsson P, Jung CK, Junjie X, Jurj PB, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Karlen D, Kasetti SP, Kataoka Y, Katori T, Kato Y, Kearns E, Khabibullin M, Khotjantsev A, Kikawa T, Kikutani H, Kim H, Kim J, King S, Kisiel J, Knight A, Knox A, Kobayashi T, Koch L, Koga T, Konaka A, Kormos LL, Koshio Y, Kostin A, Kowalik K, Kubo H, Kudenko Y, Kukita N, Kuribayashi S, Kurjata R, Kutter T, Kuze M, Labarga L, Lagoda J, Lamoureux M, Laveder M, Lawe M, Licciardi M, Lindner T, Litchfield RP, Liu SL, Li X, Longhin A, Ludovici L, Lu X, Lux T, Machado LN, Magaletti L, Mahn K, Malek M, Manly S, Maret L, Marino AD, Marti-Magro L, Martin JF, Maruyama T, Matsubara T, Matsushita K, Matveev V, Mavrokoridis K, Mazzucato E, McCarthy M, McCauley N, McElwee J, McFarland KS, McGrew C, Mefodiev A, Metelko C, Mezzetto M, Minamino A, Mineev O, Mine S, Miura M, Bueno LM, Moriyama S, Morrison J, Mueller TA, Munteanu L, Murphy S, Nagai Y, Nakadaira T, Nakahata M, Nakajima Y, Nakamura A, Nakamura KG, Nakamura K, Nakayama S, Nakaya T, Nakayoshi K, Nantais C, Naseby CER, Ngoc TV, Niewczas K, Nishikawa K, Nishimura Y, Noah E, Nonnenmacher TS, Nova F, Novella P, Nowak J, Nugent JC, O’Keeffe HM, O’Sullivan L, Odagawa T, Okumura K, Okusawa T, Oser SM, Owen RA, Oyama Y, Palladino V, Palomino JL, Paolone V, Pari M, Parker WC, Parsa S, Pasternak J, Paudyal P, Pavin M, Payne D, Penn GC, Pickering L, Pidcott C, Pintaudi G, Guerra ESP, Pistillo C, Popov B, Porwit K, Posiadala-Zezula M, Pritchard A, Quilain B, Radermacher T, Radicioni E, Radics B, Ratoff PN, Reinherz-Aronis E, Riccio C, Rondio E, Roth S, Rubbia A, Ruggeri AC, Ruggles CA, Rychter A, Sakashita K, Sánchez F, Santucci G, Schloesser CM, Scholberg K, Schwehr J, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shah R, Shaikhiev A, Shaker F, Shaykina A, Shiozawa M, Shorrock W, Shvartsman A, Smirnov A, Smy M, Sobczyk JT, Sobel H, Soler FJP, Sonoda Y, Steinmann J, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Sztuc AA, Tada M, Tajima M, Takeda A, Takeuchi Y, Tanaka HK, Tanaka HA, Tanaka S, Thompson LF, Toki W, Touramanis C, Towstego T, Tsui KM, Tsukamoto T, Tzanov M, Uchida Y, Uno W, Vagins M, Valder S, Vallari Z, Vargas D, Vasseur G, Vilela C, Vinning WGS, Vladisavljevic T, Volkov VV, Wachala T, Walker J, Walsh JG, Wang Y, Wark D, Wascko MO, Weber A, Wendell R, Wilking MJ, Wilkinson C, Wilson JR, Wilson RJ, Wood K, Wret C, Yamada Y, Yamamoto K, Yanagisawa C, Yang G, Yano T, Yasutome K, Yen S, Yershov N, Yokoyama M, Yoshida T, Yu M, Zalewska A, Zalipska J, Zaremba K, Zarnecki G, Ziembicki M, Zimmerman ED, Zito M, Zsoldos S, Zykova A. Constraint on the matter–antimatter symmetry-violating phase in neutrino oscillations. Nature 2020; 580:339-344. [DOI: 10.1038/s41586-020-2177-0] [Citation(s) in RCA: 188] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 03/03/2020] [Indexed: 11/09/2022]
|
42
|
Motoki Y, Sugimoto K, Matsushita K, Sakisaka H, Akiyama Y, Nakano K, Nakaguchi K, Doi S. [A Case of Advanced Rectal Cancer with the Metastatic Abdominal Aortic Bifurcation Lymph Node Performed by Laparoscopic Surgery after Chemotherapy]. Gan To Kagaku Ryoho 2020; 47:667-669. [PMID: 32389978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
A 63-year-old underwent examination for constipation and was found to have an unresectable advanced rectal cancer. Metastatic abdominal aortic bifurcation lymph node and lung metastasis were suspected upon CT(cT3N3M1a[PUL1], cStage Ⅳa), and chemotherapy was administered(CapeOX plus Bmab). After 4 courses of chemotherapy, the size of the primary tumor and the lymph nodes decreased(PR). We performed laparoscopic rectum resection and abdominal aortic bifurcation lymph node. The pathological diagnosis indicated partial response(residual cancer cells)(Grade 1a). After 4 courses of chemotherapy(CapeOX), we performed pulmonary partial resection for metastatic lung cancer. This case suggests that laparoscopic resection of rectum after chemotherapy with CapeOX plus Bmab for locally advanced rectal cancer is a potential- ly effective procedure.
Collapse
|
43
|
Liyanage T, Toyama T, Ninomiya T, Perkovic V, Woodward M, Fukagawa M, Matsushita K, Praditpornsilpa K, Seong H, Iseki K, Lin M, Stirnadel-Farrant H, Jha V, Jun M. SUN-107 THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN ASIA – A SYSTEMATIC REVIEW AND ANALYSIS. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
44
|
Hicks C, Daya N, Black J, Matsushita K, Selvin E. Race and sex-based disparities associated with carotid endarterectomy in the Atherosclerosis Risk in Communities (ARIC) study. J Vasc Surg 2020. [DOI: 10.1016/j.jvs.2019.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
45
|
Carmona A, Marchandot B, Kibler M, Trimaille A, Heger J, Peillex M, Matsushita K, Ristorto J, Hoang V, Hess S, Jesel L, Ohlmann P, Morel O. Impact of incomplete coronary revascularization on late ischemic and bleeding events after transcatheter aortic-valve Replacement. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
46
|
Sakata K, Mitsuda H, Ito J, Isaka A, Furuya M, Minamishima T, Matsushita K, Soejima K. P1802 Prevalence and prognostic significance of pulmonary artery aneurysms in patients with pulmonary artery hypertension. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.1155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Pulmonary artery aneurysm (PAA) occurs in some patients with pulmonary arterial hypertension (PAH) and can be accompanied by various complications.
Objective
The aim of the this study is to evaluate the characteristics of cardiac dysfunction and the prognostic impact of PAA by analysing the outcome of patients with PAH complicated by PAA.
Methods
We performed echocardiography and right-heart catheterization in 130 PAH patients. We measured the maximum dimensions of the main pulmonary artery (MPA) trunk. We evaluated the right ventricular (RV) function and the five-year prognosis of patients with PAA.
Results
The maximum MPA trunk diameter of >40 mm by echocardiography was defined as PAA. PAA appeared in 32 of the 130 PAH patients (24.6%: Group PAA), other 98 patients were defined as Group non-PAA. Systolic pulmonary artery pressure (76 ±18 vs. 61 ± 21 mmHg, P = 0.0008) and mean right atrial pressure (10.0 ± 8.1 vs. 5.4 ± 3.8 mmHg, P < 0.0001) were significantly higher in Group PAA than in Group non-PAA. RV end-diastolic area index was significantly larger (37.3 ± 8.8 vs. 32.3 ± 7.8 mmHg, P = 0.0048), and RV fractional area change (32 ± 8 vs. 36 ± 9 %, P = 0.0176) and RV longitudinal strain amplitude (-16 ±5 vs. -20 ± 6, P = 0.0017) were significantly lower in Group PAA than those in Group non-PAA. During the five-year follow-up period, 20 patients (15%) died. The five-year mortality rate was significantly higher in Group PAA compared to Group non-PAA (30% vs. 10%, P = 0.007).
Conclusion
In PAH patients with PAA, RV dysfunction was more severe and the prognosis was poor. Assessment of PAA can be a useful index for the extraction of high-risk PAH patients.
Collapse
Affiliation(s)
- K Sakata
- Kyorin University School of Medicine, Tokyo, Japan
| | - H Mitsuda
- Kyorin University School of Medicine, Tokyo, Japan
| | - J Ito
- Kyorin University School of Medicine, Tokyo, Japan
| | - A Isaka
- Kyorin University School of Medicine, Tokyo, Japan
| | - M Furuya
- Kyorin University School of Medicine, Tokyo, Japan
| | | | - K Matsushita
- Kyorin University School of Medicine, Tokyo, Japan
| | - K Soejima
- Kyorin University School of Medicine, Tokyo, Japan
| |
Collapse
|
47
|
Lachmet Thebaud L, Marchandot B, Matsushita K, Dagrenat C, Peillex M, Reydel A, Trinh A, Ohlmann P, Jesel L, Morel O. Systemic inflammatory response syndrome is a major determinant of late cardiovascular outcome in Takotsubo syndrome. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
48
|
Trimaille A, Marchandot B, Kibler M, Heger J, Peillex M, Carmona A, Matsushita K, Trinh A, Reydel A, Zeyons F, Petit-Eisenmann H, Jesel L, Ohlmann P, Morel O. Outcomes of patients with active cancer undergoing transcatheter aortic-valve replacement. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
49
|
Jimenez C, Ohana M, Marchandot B, Kibler M, Carmona A, Peillex M, Heger J, Trimaille A, Matsushita K, Reydel A, Hess S, Jesel L, Ohlmann P, Morel O. Impact of anti-thrombotic regimen and platelet inhibition extent on leaflet thrombosis detected by cardiac MDCT after transcatheter aortic-valve replacement. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
50
|
Heger J, Trimaille A, Kibler M, Marchandot B, Peillex M, Carmona A, Matsushita K, Trinh A, Reydel A, Zeyons F, Petit-Eisenmann H, Jesel L, Ohlmann P, Morel O. Electrocardiographic strain pattern is a major determinant of rehospitalization for heart failure after Transcatheter Aortic-Valve Replacement. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2019.09.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|